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ABSTRACT
The human placenta contains many hormones identical to those of
the hypothalamo-pituitary axis. It was proposed, in the 1950s that
these may influence the hypothalamo-pituitary-adrenal axis of both
the fetus and the mother. More recently it has been suggested that
placental corticotrophin-releasing hormone (CRH) and
adrenocorticotrophic hormone (ACTH) may play an important role in
the mechanism initiatiating parturition. The plasma concentration of
CRH is known to increase with gestation rising to high levels prior
to delivery. In vitro studies have investigated the modulation of its
synthesis, and have led to suggestions that it is involved in a
positive feedback mechanism leading to birth. The studies described
in this thesis were undertaken to investigate the control of its
production in vivo. Less is known about placental ACTH, and
disagreement exists over whether its output increases during
pregnancy. Studies to clarify this point, and to investigate the
modulation of ACTH production were also performed.
The cellular localisation of placental CRH has previously been
investigated using immunocytochemistry, but results are conflicting.
The results discussed in this thesis are in agreement with the more
recent of these studies. Immunoreactive CRH was localised to the
syncytiotrophoblasts of the placenta and to the amnion, chorion and
decidua throughout gestation. Since it has been hypothesised that
CRH may play a role in the onset of parturition, the effects of
labour on both immunostaining, and placental CRH content were
investigated. There was no difference in placentas collected after
spontaneous delivery compared with those from women who had
not laboured. Previous in vitro studies have suggested that
prostaglandins may stimulate, and progesterone may inhibit,
placental CRH production. Placentas collected after prostaglandin
induced delivery in the first and second trimesters, and at term
were studied. There was found to be no difference in either
immunostaining, or in placental CRH content in any of these tissues
compared to tissues collected after suction curettage, or spontaneous
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delivery. The effect of progesterone was studied using the
antiprogestin mifepristone in the first trimester. Tissues collected after
termination of pregnancy with mifepristone showed no differences to
those collected after curettage.
These studies are the first to localise POMC gene expression
within the placenta by in situ hybridisation. In combination with
immunocytochemistry both mRNA transcribed from the gene, and
the gene product translated from the mRNA can be identified. The
results of these studies provide very strong evidence that POMC is
synthesised in cytotrophoblasts in the first trimester, and
syncytiotrophoblasts thereafter. In addition both POMC mRNA and
immunopositive staining were found in amnion and chorion. The
placental ACTH content increased with advancing gestation, and
this finding was supported by both an increase in immunostaining
and POMC gene expression over this period. Placental ACTH
content, immunostaining and POMC gene expression were unaffected
by labour, the administration of prostaglandins in the first trimester
and at term, or by the administration of mifepristone in the first
trimester.
Thus both CRH and ACTH appear to be constitutively present in
the placenta throughout gestation. These results suggest that these
peptides may have other roles during pregnancy rather than being
simply related to parturition. They contribute to the normal endocrine
environment of the placenta and may have a 'housekeeping' role
throughout pregnancy. In addition, they may also enter the fetal
circulation influencing its hypothalamo-pituitary-adrenal axis and
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The placenta contains many hormones that are identical or similar to
those of the hypothalamo-pituitary axis. In particular it synthesises
corticotrophin-releasing hormone (CRH), the plasma concentration of
which rises with advancing gestation. CRH is thought to play an
important role in the mechanism by which parturition is initiated. In
addition, the presence of an adrenocorticotrophin-like hormone has
been demonstrated in placenta. Both these hormones may influence the
hypothalamo-pituitary-adrenal axis of the fetus and also possibly the
mother, and, at the same time have a paracrine/autocrine role within
the placenta and fetal membranes.
This review will deal with the anatomical and histological structure of
the human placenta, the placenta as an endocrine organ and then give
a brief overview of the physiology and biochemistry of normal labour.
It will also review the historical background to the discovery of CRH,
both hypothalamic and placental, including its hypothesised intracellular
mode of action on the corticotroph, the changes in CRH during
pregnancy in maternal plasma, fetal plasma and amniotic fluid and its
interactions with CRH-binding protein. It will then discuss CRH in the
placenta and fetal membranes including its tissue and cellular origins,
the control of CRH production by the placenta and fetal membranes
including its relevant molecular basis, and its interactions with steroid
hormones, prostaglandins and oxytocin. Finally, it will discuss the
suggested role that placental CRH may play in parturition. Background
information will be provided of the discovery of ACTH in the
placenta, the changes in plasma and placental levels during pregnancy
and the control of its production. It will then suggest possible
explanations for the role of ACTH in pregnancy.
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1.2. The structure of the placenta and fetal membranes
1.2.1. The placenta
The human placenta consists of layers of trophoblast cells, connective
tissue and branching blood vessels which are all of fetal origin.
As early as the third week of gestation, there is a villous system
capable of supplying the embryo with nutrients and oxygen.
The primary stem villus, consisting of a cytotrophoblast core
surrounded by a syncytial layer, is penetrated by mesoderm to form
the secondary stem villus. These mesodermal cells differentiate to form
the fetal capillaries of the tertiary stem villus, by the fourth week of
gestation, connecting the placenta with the embryo. By the end of the
eighth week, the trophoblast consists of a great number of secondary
and tertiary villi the surface of which is formed by the
syncytiotrophoblasts resting on a layer of cytotrophoblasts covering the
fetal capillary system. In the mature placenta, villi of
syncytiotrophoblast, containing mesodermal cores in which fetal blood
vessels run, penetrate deeply into maternal tissue (the decidua).
Each villus, formed by progressive branching of the main divisions of
the umbilical vessels is separated from the surface by a thin
syncytiotrophoblast layer. The branches of the villi are arranged in
lobules with the terminal villi projecting inwards with a maternal
spiral artery at the base of each lobule which injects blood into the
space. There are approximately two hundred such lobular units and
several are grouped together to form a cotyledon. Maternal blood
circulates around the terminal villi containing the fetal capillaries and
both active transport and passive diffusion of molecules occurs across
this membrane depending on such factors as molecular weight, electrical
charge and hydrophobicity. The chorionic villi are thus the functional
unit of the placenta. Each is surrounded by an outer layer of
syncytiotrophoblast and an inner layer of cytotrophoblast.
The syncytiotrophoblast is a continuous layer covering the villi, and on
the maternal side, is in direct contact with maternal blood.
Morphologically the trophoblasts may be cellular (cytotrophoblasts)
syncytial (syncytiotrophoblasts) or intermediate. Mitotic figures are
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completely absent from the syncytium, being confined purely to the
cytotrophoblasts. Midgely (1963) found that although Tritium-labelled
thymidine appeared at first only in the nuclei of the cytotrophoblasts, it
could be detected twenty-two hours later in the syncytiotrophoblast.
It therefore seems likely that the syncytium is derived from
cytotrophoblast and is a mitotic end stage. Thus, cytotrophoblasts are
prominent in first trimester placenta, but, as they differentiate into
syncytiotrophoblast, they are sparse at term. A basement membrane lies
between the trophoblast and the stroma. The stroma contains loose
mesenchymal tissue, macrophages (Hofbauer cells) and fetal capillaries
(one to six per villus). The chorionic villus consists of thick areas
containing the organelles for synthetic functions and thin areas
overlying fetal capillaries (vasculosyncytial membranes) that are
specialised for transfer between maternal and fetal circulations. Of all
the placental components, the trophoblast is the most variable in terms
of structure, function and development and has the most diverse roles.
These include attachment and nutrition of the early conceptus,
prevention of maternal rejection, transfer of substances between the
maternal and fetal circulations, and as an endocrine organ secreting a
large number of steroid and peptide hormones, enzymes and placental
proteins. (For the structure of placental villi at term and in the first
trimester, see figure 1.1)
1.2.2. The amnion
The amnion develops from fetal ectoderm and arises as a layer of
epithelial cells between the ectodermal disc of the inner cell mass and
the trophoblast (chorion). The amnion is 0.02-0.5mm thick and has five
layers comprising cuboidal epithelium with a microvillus surface,
prominent intracellular canals and numerous vacuoles, basement
membrane, the compact layer, fibroblastic layer and the spongy layer of
mucoid reticular tissue. It is avascular and aneuronal and has no
lymphatics. It also has diverse roles including the production of
amniotic fluid and prostaglandin synthesis. (For the structure of the
amnion, see figure 1.2)
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1.2.3. The chorion
Chorion has only four layers, comprising a cellular layer of fibroblasts,
a reticular layer, a basement membrane and then trophoblast.
The trophoblast layer is two to ten cells thick, and is continuous with
placental trophoblast, lying adjacent to decidua. In placental areas
chorion contains both a vascular and a nervous supply, but elsewhere
is avascular and aneuronal. As well as its synthetic functions, it has
substantial prostaglandin dehydrogenase activity.
(For a diagram of the structure of chorion, see figure 1.2).
1.2.4. The decidua
Unlike the amnion, chorion and trophoblast, the decidua is maternally
derived. It is the endometrium of the pregnant uterus, thickening
throughout gestation, to become 10mm thick. The decidua adjacent to
the site of implantation is the decidua basalis, that overlying the
developing embryo is the decidua capsularis, and the rest of the uterus
is lined by the decidua parietalis. After the fourth month of pregnancy,
the decidua parietalis and capsularis fuse, and the uterine cavity is
obliterated. Decidual stromal cells are large polyhedral epitheliod cells
surrounded by a basement membrane. The decidua is thought to be
concerned with the nutrition of the blastocyst (Kearns and Lala 1983),
trophoblast invasion (Kishimoto et al 1987) and protection of the
embryo from maternal immune rejection (Golander et al 1984).
1.3. The placenta as an endocrine organ
1.3.1. Placental steroid hormones
The placenta in many species is the source of many steroid and peptide
hormones. The placental synthesis of steroid hormones is a vast
subject, and since this thesis will focus on placental peptides, steroids
will only be discussed here briefly. As mentioned above, during
pregnancy the placenta undergoes a continuous differentiation process,
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with cytotrophoblasts differentiating into syncytiotrophoblasts. Using
immunohistochemical techniques investigators have localised steroid
hormones to the syncytiotrophoblast. Large amounts of oestrogens,
progesterone and pregnenolone are produced during pregnancy. By the
eighth week, the placenta has started to produce progesterone
(Tulchinsky and Hobel 1973), and as much as 600mg is produced per
day by late pregnancy. Steroid precursors from the fetus such as
dehydroepiandrosterone sulphate and 16a-hydroxydehydroepiandrosterone
are converted by placental sulphatases and aromatases to oestradiol and
oestriol respectively (Bolte et al, 1964; Sitteri and Macdonaldl963; Klausner
and Ryan 1964; Sitteri and Macdonaldl966). (See figure 1.3 for a flow
diagram of placental steroid production and metabolism)
1.3.2 Placental peptide and polypeptide hormones
Almost all the placental peptide or polypeptide hormones investigated
are structurally and functionally either identical or very similar to their
pituitary and hypothalamic counterparts. Thus placental lactogen shares
properties with prolactin, chorionic gonadotrophin is similar to
luteinising hormone, placental pro-opiomelanocortin (POMC) derived
peptides are similar to those produced by the pituitary, and a number
of peptides, including CRH, are produced that are very similar to
hypothalamic hormones, (see figure 1.4)
1.3.2.1. Placental pituitary-type hormones
Pituitary-type hormones, HCG, HPL and POMC peptides have been
primarily localised to the syncytiotrophoblast (Al-Timini and Fox 1987)
and some studies have located hypothalamic-type peptides to the
cytotrophoblast (Petraglia et al 1987; Saijonmaa et al 1988) or the
syncytiotrophoblast (Riley et al 1991). In vitro studies have shown that
GnRH stimulates the release of trophoblastic HCG production (Merz et
al 1991; Kelly et al 1991), and CRH stimulates placental ACTH
production (Margioris et al 1988a) leading to speculation that the
cytotrophoblast may regulate syncytiotrophoblast function in a paracrine
manner (Petraglia et al 1990b). In addition, these neuropeptides may enter
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the maternal and fetal circulations and exert endocrine effects
(Gennazzani et al 1975; Goland et al 1986; Economides et al 1987).
Placental production of POMC peptides will be discussed in detail in
later sections. In addition to POMC peptides, the placenta produces
other pituitary-type hormones.
Human chorionic gonadotrophin (HCG) is one of the earliest hormones
to be detected in pregnancy and is essential for the maintainence of the
corpus luteum of pregnancy (Braunstein 1988). Its regulation is different
to that of other placental proteins in that its levels peak in late first
trimester and then fall whilst other placental hormones show a
continual increase correlating with increasing placental mass
(Braunstein et al 1976). The regulation of its synthesis is not well
understood but may involve factors produced by decidua and
trophoblast (Vicovac and Genbacevl988; Yagel et al 1989; Masuhiro et al
1991; Yuen et al 1986).
Placental lactogen can first be detected in plasma as early as 6 weeks
gestation (Grumbach and Kaplan 1964), and its secretion increases linearly
to
30 weeks (Grumbach et al 1968). It has been suggested that placental
lactogen acts as an insulin antagonist in the mother, inducing lipolysis
and proteolysis, thus facilitating the transfer of glucose and amino acids
to the fetus (Grumbach et al 1968). More recently, it has been suggested
that placental lactogen may affect fetal growth by a direct action on the
fetus (Freemark and Handwerger 1989). Placental lactogen was, for many
years, thought to be the only sommatomammotrophin produced by the
placenta, however the syncytiotrophoblast also produces a peptide similar
to pituitary growth hormone (Frankenne et al 1988), and the decidua
produces prolactin (Golander et al 1978; Riddick et al 1978; Rosenberg et
al 1980).
Placental growth hormone is thought to have similar action in the
mother as placental lactogen, and it has been suggested that decidual
prolactin may play a role in the regulation of amniotic fluid volume
(Tyson et al 1984), the regulation of fetal lung surfactant synthesis
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(Grosso et al 1980), and the modulation of prostaglandin synthesis in
the fetal membranes (Tyson et al 1985).
1.3.2.2. Placental hypothalamic-type hormones
In addition to CRH (which will be discussed in detail in later sections)
other hypothalamic releasing or inhibiting hormones are produced by
the placenta. Placental gonadotrophin-releasing hormone (GnRH) has
been localised to the cytotrophoblast and is immunologically and
biologically indistinguishable from hypothalamic GnRH (Gibbons et al
1975; Khoder and Siler-Khoder 1980; Lee et al 1981). Its release is
modulated by steroid hormones, opioids, prostaglandins and
noradrenaline (Petraglia et al 1987a; Petraglia et al 1990b). GnRH has a
paracrine role stimulating the release of HCG from cultured placental
tissue throughout gestation (Siler-Khoder 1983; Khoder and Siler-Khoder
1978; Siler-Khoder and Khoder 1989).
A thyrotrophin-releasing hormone like substance has been found in
human placenta (Gibbons et al 1975), and a growth hormone releasing
hormone has been identified in rat placenta (Baird et al 1985).
The function of both these peptides within the placenta is unknown.
For most placental peptides and proteins a definitive physiological role
has not been established. Instead, it has been suggested, that many of
the placental proteins and peptide hormones exist to maintain the
trophoblast as a functional unit, providing information about the
maternal environment, rather than having specific endocrine actions.
This view is supported by the finding that normal pregnancy can occur
when specific peptides, for example prolactin, (Simon et al 1986) are
absent. The synthesis of these peptides would enable a fairly constant
level of general activity throughout the trophoblast, maintaining
constant transfer of waste and nutrients between fetal and maternal
circulations (Chard 1993).
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1.4. The physiology and biochemistry of labour
Effective labour involves both ripening and dilation of the cervix and
the production of coordinated uterine contractions capable of expelling
the conceptus. Uterine contractions occur throughout pregnancy
(Caldeyro-Barcia 1959) and increase in strength over the last five weeks
of pregnancy, reaching a maximum during labour. Over the same
period a number of structural changes cause the cervix to soften, dilate,
and become effaced (Anderson and Turnbull 1969). The cervix is
composed of fibrous connective tissue, the main component of which is
collagen fibrils bound together by the proteoglycan complexes of the
ground substance (Van der Rest 1980). Proteoglycans are
glycosaminoglycans, particularly dermatan sulphate in the human cervix,
connected to a protein core (Uldbjerg et al 1983b). The sulphate group
on this mucopolysaccharide makes it extremely hydrophilic and it is
this modification of the cervical water content that alters the
mechanical properties of the cervix (Uldjberg et al 1983c). The softening
of the human cervix is due to marked changes in the connective tissue
(Danforth 1983) with an increase in water content and a change in the
content of glycosaminoglycans (Von Maillot et al 1979; Uldjberg et al
1983a). Compared with the non-pregnant cervix there is fall in collagen
content of more than 50% (Uldjberg et al 1983c). In addition, the
number of intermolecular cross-links is decreased causing the dispersal
of collagen fibrils, with resulting softening of the cervix (Junqueira et al
1980). Prostaglandins are involved in the control of this process. The
evidence for this comes from clinical as well as physiologcal and
pharmacological studies. There is a correlation between concentrations of
prostaglandins E2 and F20C in amniotic fluid, and the degree of cervical
ripening (Calder 1980), and prostaglandin E2 is used to ripen the cervix
prior to the induction of labour (Calder 1980; Greer et al 1989). PGE2
reduces the collagen content of the cervix (Uldjberg et al 1983c),
although whether this is due to an increase in collagenase activity
(Uldjberg et al 1983; Szalay et al 1981), or by altering the composition of
glycosaminoglycans in the ground substance (Cabrol et al 1987) is
unclear. The importance of a local factor in cervical ripening is
supported by experiments on isolated sheep cervix, where, despite the
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loss of vascular and mechanical connections, softening still occured in
labour (Ledger et al 1985). This experiment showed that cervical ripening
is an active rather than a passive process and is not secondary to
uterine activity. In addition oestradiol (Gordon and Calder 1977) and
relaxin (MacLennan et al 1986) have been implicated in cervical
ripening. Steroid hormones such as oestradiol may have effects on
cervical ripening by a direct action or via changes mediated by
prostaglandins.
As discussed above, the uterus is never entirely quiescent, but the
nature of this activity at term, is entirely different to that in the first
trimester. Several factors play a role in the transition from the uterus
as a 'capacitance vessel' in early pregnancy, to that capable of expelling
the fetus at term. Like the cervix, the body of the uterus has a matrix
of collagen fibres. In this are embedded smooth muscle cells containing
random bundles of actin and myosin (Marsten and Smith 1985) and it is
through the interaction of these two molecules that contractions are
generated. The interaction of actin and myosin in the mometrial cells is
under the control of intracellular calcium levels (Carsten and Miller
1987). Prostaglandins E2 and F20C and oxytocin increase the availability
of intracellular calcium and therefore stimulate uterine activity (Carsten
and Miller 1987). During the last few weeks of pregnancy, and during
labour, intercellular connections (gap junctions) develop. These junctions
allow the cells to communicate both metabolically and
electrophysiologically thus converting disparate myometrial cells to a
functional syncytium (Garfield et al 1977; Garfield et al 1980a; Garfield
and Hyashi 1981). The formation of these gap junctions is also under
the control of steroids and prostaglandins (Garfield et al 1980);
prostaglandins F2a and E2 and oestrogens stimulate, and progesterone
and prostacyclin inhibit, gap junction formation. In addition, the
antiprogestin mifepristone will induce gap junction formation.
Progesterone decreases electrical conductivity between cells and inhibits
the formation of gap junctions (McKenzie and Garfield 1985). Conversely,
oestrogens reduce the membrane resting potential of cells, increase
intracellular calcium ion concentrations and increase gap junction
formation and thus stimulate myometrial contractility.
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The activity of the uterus prior to labour thus depends on a balance of
stimulatory and inhibitory factors, the appearance of gap junctions
which allows synchrony between myometrial cells, and changes in
membrane potentials. In sheep, parturition is preceded by a rise in the
plasma concentrations of the myometrial stimulants oestrogens and
prostaglandins combined with a fall in the plasma concentration of the
myometrial relaxant progesterone (Csapo 1961). Such a fall does not
occur in humans although the antiprogestin mifepristone increases the
myometrial sensitivity to prostaglandins and is an effective abortifacent
in humans and animals (Rodger and Baird 1987; Rodger et al 1988;
Garfield and Baulieu 1987). Oestrogens may also stimulate prostaglandin
production (Olsen et al 1983).
Prostaglandins play an important role in the generation of uterine
contractility. Both PGE2 and PGF2a levls rise in amniotic fluid (Keirse
1979; Hillier et al 1974 ), and both metabolites rise in plasma during
labour (Johnston et al 1990). The plasma concentrations of PGF2a
during labour correlate directly with the duration and inversely with
the need for augmentation, suggesting it is important for generating
and maintaining uterine activity. The levels of PGE2 rise prior to the
onset of established labour and it is the major prostaglandin produced
by the amnion (Johnston et al 1990). It has high affinity receptors in
the myometrium (Adelantado et al 1985) implicating it in the regulation
of uterine contractility.
Over the last few weeks of pregnancy, and during the first stage of
labour, the number of myometrial receptors for oxytocin increases
(Alexandova and Soloff 1980; Fuchs et al 1982) with a resultant increase
in sensitivity to oxytocin (Caldeyro-Barcia and Sereno 1961). At this time,
the plasma level of oxytocin remains at a constant level (Thornton et
al 1988). Oxytocin acts by increasing intracellular calcium availability
and thus increases the contractions in a previously sensitised uterus
(Fuchs 1983). Oestrogens increases (Alexandrova and Soloff 1980) and
progesterone reduces (Soloff 1985) the concentration of oxytocin receptors
and prostaglandins increase the uterine sensitivity to oxytocin.
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Thus, steroid hormones and prostaglandins (regarded as the final
common mediators of parturition) are involved in the regulation of
both cervical ripening and myometrial contractility. Parturition in the
sheep appears to be controlled by maturation of the fetal hypothalamo-
pituitary-adrenal axis (Challis and Brooks 1989). The fetal hypothalamus
secretes CRH which in turn stimulates the production of ACTH from
the fetal pituitary over the last few weeks of gestation (Brooks and
Challis 1988). The ACTH stimulates the production of Cortisol from the
fetal adrenal and this increases the activity of placental 17-hydroxylase,
causing the conversion of progesterone to oestrogen (Flint et al 1975).
Thus there is a change in the balance of myometrial stimulants and
relaxants in favour of stimulants, thus resulting in increased gap
junction formation production, myometrial excitability and prostaglandin
production. In contrast, the human placenta is deficient in 17-
hydroxylase. This means that there can be no placental conversion of
progesterone to oestrogen. Indeed, there is no change in the plasma
concentrations of these hormones at the onset of labour (Liggins 1983).
However, a rise in fetal Cortisol does occur, and there is further
evidence of HPA axis activation in the rapidly rising levels of CRH
prior to delivery (see sections 1.6-1.9). Maturation of the fetal HPA axis
may affect the axis of hypothalamo-pituitary peptides produced by the
placenta. Placental CRH and ACTH pass to the fetal circulation
stimulating the fetal adrenal to produce Cortisol and DHEA sulphate
which in turn may be converted to oestradiol by placental aromatase. In
addition, fetal Cortisol may increase placental CRH production in a
unique positive feedback mechanism (Jones et al 1989). As mentioned
above, in common with the sheep, prostaglandins appear to be of
central importance in the final pathway controlling human parturition.
Placental CRH in turn, stimulates prostaglandin production by the fetal
membranes, thus linking maturation of the HPA axis hormones with
the onset of parturition.
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1.5. Hypothalamic corticotrophin-releasing hormone
Corticotrophin-releasing hormone (CRH) is a 41 amino acid peptide first
described, in the sheep, by Vale et al in 1981 and subsequently was
isolated, characterised and synthesised (Vale et al 1983). It is produced
in high concentrations by the parvocellular neurones of the
paraventricular nucleus of the hypothalamus (Pelletier et al 1983). The
axons of these neurones project to the median eminence where CRH is
secreted (Takahashi et al 1989). It is then transported from the
hypothalamus by the hypophyseal portal system and reaches the
anterior pituitary where pro-opiomelanocortin products such as
adrenocorticotrophic hormone (ACTH) and Beta-Endorphin ((3-EP) are
released (Grossman et al 1982). Ovine and human CRH both consist of
41 amino acids but seven of these, mainly found in the C-terminal
region, differ (Vale et al 1983). Screening a human gene library with an
ovine complementary DNA probe for CRH located the gene for human
CRH precursor; the sequence of human CRH was then deduced
(Shibihara et al 1983). Rat hypothalamic CRH was also found to differ
from ovine CRH by seven amino acid residues (Rivier et al 1983), but
rat and human CRH appear to be identical and their respective pre-pro
CRH exhibit an 80% homology (Jingami et al 1985).
The CRH gene has been isolated from a variety of species and shows
considerable interspecies homology. The rat and human sequences share
94% nucleotide homology, while the ovine sequence shares
approximately 80% with each of these. In humans the gene is located
on the long arm of chromosome 8 (Arbiser et al 1988).
The major role of hypothalamic CRH is to regulate the HPA axis via
the stimulation of expression of the POMC gene (Affolter and
Reisinel985) and ACTH release from the anterior pituitary gland.
However, as well as the paraventricular CRH-containing neurones,
multiple extahypothalamic sites of synthesis and action of CRH have
been determined including the placenta.
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CRH exerts its effects by binding to a high affinity membrane bound
receptor. These binding sites have been so far identified in rat and
human (DeSouza 1985) pituitary, and rat (DeSouza et al 1984) and
human(DeSouza et al 1986) brain. The CRH receptor is coupled to
adenylate cyclase (Bilezikjian and Vale 1982) through a GTP binding
protein thus mediating an increase in intracellular cyclic AMP. Using a
cDNA encoding a pituitary CRH receptor isolated from a Cushing's
adenoma (Chen et al 1993) two forms of receptor were isolated, the
alpha form consisting of a 415 amino acid protein in the form of seven
putative membrane spanning domains. It is similar in structure to the
family of G-protein coupled receptors which includes calcitonin,
vasoactive intestinal peptide and growth hormone releasing hormone
receptors. The second form of the receptor consists of a 415 amino acid
protein with an insert of 29 amino acids in the first intracellular loop.
Using the same probe, a rat brain CRH receptor was isolated (Perrin et
al 1993), which differed by 12 amino acids, representing a species or a
functional difference.
1.6. Maternal plasma CRH during pregnancy.
In 1982 a substance of similar size to hypothalamic CRH was extracted
from human term placentae and it was found that this extract could
stimulate the production of ACTH from rat anterior pituitary cell
cultures; thus it showed similar bioactivity to hypothalamic CRH
(Shibasaki et al 1982). CRH was then demonstated, by radioimmunoassay,
in the plasma of women during the third trimester of pregnancy, levels
being undetectable in normal, non-pregnant women. Chromatography of
this plasma showed that the CRH was indistinguishable from that of
placental extracts (Sasaki et al 1984). It was therefore concluded that the
placenta may be the source of the high levels of plasma CRH in late
pregnancy. In non-pregnant women, the concentration of plasma CRH
is low < lOpg/ml (Sasaki et al 1984, Suda et al 1985), it then slowly rises
during pregnancy until approximately thirty-five weeks gestation after
which it rises exponentially until term reaching nanomolar
concentrations (Goland et al 1986, Campbell et al 1987 , Cunnah et al
1986, Sasaki et al 1987, Laatikainen et al 1987b, Wolfe et al 1988a).
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Furthermore, it was seen that plasma levels were further elevated
during early labour, peaked at delivery and declined rapidly, halving
within 20-30 minutes of delivery (Schulte and Healy 1987; Laatikainen et
al 1987b), and reaching non-pregnant levels by 1-5 days post-partum
(Sasaki et al 1987; Okamoto et al 1989). In addition, maternal plasma
CRH is raised in preterm labour (Kurki et al 1991), but unaffected by
the administration of tocolytics. Longitudinal studies of plasma CRH
levels throughout pregnancy have shown that women who
subsequently went into premature labour had abnormally high levels of
CRH several weeks before delivery (Campbell et al 1987). High levels
are also seen in women with pregnancy induced hypertension (but not
chronic hypertension), twin pregnancy (although this is likely to be due
to increased placental mass) intrauterine growth retardation (possibly
secondary to placental compromise rather than just a mass effect) and
antepartum haemorrhage at twenty-eight weeks gestation (Wolfe et al
1988b, Campbell et al 1987, Okamoto et al 1989, Warren et al 1990,
Laatikainen et al 1991). Since raised CRH levels in plasma are seen
several weeks prior to premature delivery, it has been suggested that
measurement of CRH could form an important predictive test for
preterm delivery (Campbell et al 1987; Wolfe et al 1988b).
1.7. Amniotic fluid CRH
Amniotic fluid, placental, and maternal and fetal plasma CRH levels are
highly correlated (Sasaki et al 1990; Maser Gluth et al 1987; Economides
et al 1987) but maternal plasma concentrations tend to be twice as high
as amniotic fluid levels. As is the case in maternal and fetal plasma, a
significant rise in amniotic fluid CRH concentration is seen between
mid-trimester (Economides et al 1987) and the third trimester (Maser-
Gluth et al 1987; Laatikainen et al 1988; Sasaki et al 1989). This is
paralleled by an increase in the CRH gene expression in the amnion
reflected by a rising level of CRHmRNA (Okamoto et al 1990).
Concentrations of CRH in amniotic fluid were increased in patients
with diabetes and in pregnancies complicated by pre-eclampsia and
intra-uterine growth retardation. In cases of intrauterine stress such as
in pre-eclampsia with intrauterine growth retardation, fetal maturation
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is promoted by an unknown mechanism. One of the most important
features, in terms of extrauterine survival, of fetal maturation is the
production of surfactant by the fetal lungs. This occurs after twenty-four
weeks gestation during a period when the CRH levels in maternal
plasma are increasing (Sasaki et al 1984, Goland et al 1986, Campbell et
al 1987, Laatikainen et al 1987b). Laatikainen et al (1988) studied
amniotic fluid CRH concentrations in normal and in complicated
pregnancies and also related levels to known parameters of fetal lung
maturation. A lecithin/Sphingomyelin ratio >2 or a positive
phosphatidylglycerol test in amniotic fluid indicates mature fetal lungs
and these coincided with a rise in amniotic fluid CRH and Cortisol
(Laatikainen et al 1987b) suggesting that CRH may be involved, probably
via Cortisol, in the process of fetal lung maturation.
1.8. Fetal plasma CRH concentration
CRH is detectable in umbilical arterial cord plasma in both term and
preterm (between 26 and 37 weeks gestation) infants (Nagashima et al
1987). Furthermore umbilical venous CRH concentrations are higher
than umbilical arterial plasma concentrations when the samples are
taken simultaneously suggesting that the placenta is a major site of
CRH production (Goland et al 1986, Sasaki et al 1987, Goland et al 1988)
and that it secretes large amounts of biologically active CRH into the
maternal and fetal circulations during pregnancy. The umbilical arterial
plasma CRH level is extremely elevated in growth retarded compared
with normal fetuses (Goland et al 1993). This suggests that placental
CRH may be stimulated in a similar way to that from the
hypothalamus in conditions of chronic stress.
Using fetoscopy, fetal blood samples were obtained at gestations of
between sixteen and twenty-four weeks (Economides et al 1987). There
was a positive correlation between maternal and fetal plasma CRH
agreeing with the hypothesis that the placenta was the common source
of CRH for both compartments, it being unlikely that significant
quantities of CRH cross the placenta on account of its size and
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hydrophobicity. The placental CRH is secreted from the trophoblast into
the maternal villous blood and thence to the fetal circulation.
However, other groups have suggested that CRH concentrations do not
correlate well with those of ACTH or p-endorphin in either fetal or
maternal plasma, indicating that placental CRH is not the major
determinant of either fetal or maternal ACTH secretion (Goland et al
1986). However, work done prior to the studies of Economides in 1987,
did not use fetoscopy to obtain samples, instead using hysterotomy or
abortion specimens, possibly allowing more time for degradation of
peptides.
1.9. CRH in placenta, fetal membranes and myometrium
Extracts of human placenta contain corticotrophin releasing
hormone-like activity similar in activity and size to hypothalamic CRH
(Shibasaki et al 1982). When added to cultures of anterior pituitary cells
the extracts showed bioactivity with the release of ACTH and P-EP.
Furthermore when placental tissue from different stages of pregnancy
was investigated it was noted that levels of immunoreactive CRH were
much lower at ten weeks gestation than at term (Schulte et al 1987,
Frim et al 1988, Saijonmaa et al 1988) and this correlated with maternal
plasma CRH levels (Sasaki et al 1987). The effects of labour on placental
CRH have also been studied, and the mean concentration of CRH in
placental tissue was found to be significantly larger after spontaneous
vaginal delivery than at elective caesarean section performed before the
onset of labour (Saijonmaa et al 1988).
In addition to measuring CRH in placental extracts, it has also been
possible to measure CRH output from primary cultures of placenta and
fetal membranes (Jones et al 1989), and from superfused placental
fragments (Thomson et al 1988). There is an increased output of CRH
from short term cultures of cells obtained from spontaneous deliveries
compared with those from elective caesarean section.
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Thus, the increasing concentrations of CRH in placental extracts as
pregnancy progresses and during labour (Schulte and Healy 1987,
Saijonmaa et al 1988), the positive correlation between fetal and maternal
plasma CRH (Economides et al 1987) and the difference in umbilical
arterial and venous levels of CRH (Goland et all986, Sasaki et al 1983,
Goland et al 1988) all provide indirect evidence that the placenta
produces the increasing amounts of CRH seen in maternal plasma.
Further evidence to support this has been provided by the study of
CRH gene expression in the placenta. Using oligonucleotide probes and
northern blot hybridisation, CRHmRNA was detected in the human
placenta (Grino et al 1987) supporting the idea that the placenta is the
site of CRH biosynthesis. That the rising levels of CRH in pregnancy
are of placental origin was further supported by the finding that
placental CRHmRNA increases more than twenty-fold in the five weeks
preceding parturition and this parallels the placental CRH peptide
content (Frim et al 1988). Furthermore the CRHmRNA in human
placental tissue is similar in size to hypothalamic CRHmRNA and the
transcription initiation site for placental CRHmRNA is identical to that
previously predicted for hypothalamic CRHmRNA, 23-26 nucleotides
downstream from a promoter element (Frim et al 1988). CRHmRNA
has also been demonstratated in the amnion (Okamoto et al 1990), in
increasing amounts through gestation. It may be responsible for the
increasing concentrations of CRH in the amniotic fluid during gestation
(Laatikainen et al 1988). In the decidua, like placenta and amnion, the
expression of CRHmRNA was higher at term than during the first and
second trimester (Petraglia et al 1992).
1.10. CRH localization at a cellular level
In the late 1980s two studies used immunohistochemical techniques to
localize CRH to the cytotrophoblast cells of the placenta (Petraglia et al
1987, Saijonmaa et al 1988) but their results were conflicting in two
respects. Saijonmaa et al found positive immunoreactive CRH staining
in the cytotrophoblast cells of first trimester placenta, but were unable
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to show staining in term placenta. However Petraglia et al, using
indirect immunofluorescence suggested that immunoreactive CRH was
present in only term placenta. As gestation proceeds the number of
cytotrophoblasts decreases to a relatively small number at term. If these
were the CRH producing cells this would not be consistent with the
rising CRH content of placental extracts and CRHmRNA content with
increasing gestation.
More recent work by Riley et al (1991) used an ovine polyclonal CRH
antibody and placentas of different gestations from normal and
pathological pregnancies. They found that positive CRH staining was
localized to the syncytiotrophoblast and the intermediate trophoblast but
not the cytotrophoblast. From week twenty of gestation onwards the
distibution of CRH staining was the same in placentas obtained from
normal births, preterm births, pregnancies complicated by pre-eclampsia
and post term births. CRH was also localized in the epithelium and
subepithelial layer of the amnion, the reticular layer of chorion, the
invasive trophoblast and the stromal cells of the decidua. In diabetic
pregnancies, where there are an increased number of cytotrophoblast
cells at term, the placentas showed no positive staining of
cytotrophoblast at this time. The presence of CRH immunoreactivity in
amnion, chorion and decidua is consistent with the release of CRH by
these tissues in primary culture. The number of syncytiotrophoblast
cells at term is relatively high and, considering the large output of
CRH at this time, this is maybe more likely to be the site of secretion.
In addition, the syncytiotrophoblast has been shown to be the site of
synthesis for other placental peptide and glycoprotein hormones (see
sections 1.3.2.1-1.3.2.2).
1.11. CRH - binding protein
As described above plasma levels of CRH are markedly raised by the
third trimester of pregnancy. Despite this, plasma levels of ACTH
remain within the normal range at this time. In addition, direct
radioimmunoassay of human CRH in unextracted plasma show spurious
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results suggestive of some interfering factor in the plasma (Ellis et al
1988). Several groups have reported the existence of a binding protein
with a large capacity to bind CRH which may explain these anomalies
(Linton and Lowry 1986; Suda et al 1988). Sephadex G50 chromatography of
unextracted human pregnant plasma at a neutral pH shows two peaks,
the largest eluting in the void volume. When the plasma is pretreated
with urea all the CRH elutes in the expected position suggesting that
the peptide is bound to a large molecular weight carrier substance
(Linton et al 1988). This carrier substance was later identified by
electophoresis and autoradiography as a 37kDa protein of 322 amino
acids (Orth and Mount 1987; Behan, Linton and Lowry 1989; Potter et al
1991). It is unlikely that the binding protein is a form of CRH receptor
as it is considerably smaller and does not bind to ovine CRH (unlike
the human CRH receptor) (Suda et al 1988), and CRH BP has no
sequence homology with the cloned receptor (Chen et al 1993). Some
regions of the brain express both the CRH receptor and the CRHBP
(Potter et al 1992), but the functional relationship between the two
remains to be determined.
CRHBP is expressed in human liver, placenta and brain, and in rat
brain (Potter et al 1991; Potter et al 1992). CRHBP gene expression and
peptide have been colocalized using human CRHBP cDNA riboprobes
and immunocytochemistry to the syncytiotrophoblasts of human term
placenta (Petraglia et al 1993). The local production of CRHBP by the
trophoblast may be a mechanism by which the placenta may control
CRH activity during pregnancy. As mentioned above, primate CRH
binding protein mRNA is expressed in liver, placenta and brain,
whereas in the rat CRHBP mRNA has only been observed in the
brain (Potter et al 1991). The difference in tissue expression could reflect
an adaptation in primates which prevents inappropriate pituitary effects
of placental CRH during gestation. In contrast the rat placenta does not
produce significant amounts of CRH and therefore a binding protein
would not be needed to protect the pituitary.
The existence of this binding protein at concentrations sufficiently high
to bind nanograms of CRH (such levels are seen in late pregnancy, as
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previously discussed) probably explains the problems encountered in the
development of radioimmunoassays for the direct measurement of
hCRH in human plasma. It seems that the binding protein interferes
with CRH antisera (Orth and Mount 1987). No such interference is seen
when measuring ovine CRH in human plasma by radioimmunoassay
(Nicolson et al 1983) suggesting that the binding protein does not bind
to ovine CRH (Linton et al 1987). Specific immunoradiometric assays
have been devoloped that are not affected by the presence of CRH-
binding protein in plasma. These report a considerably shorter half life
for ovine CRH in man (42 mins)( Saphier et al 1992) compared with
that measured by radioimmunoassay (55-73 mins) (Nicolson et al 1983,
Schulte et al 1984, Schurmeyer et al 1984). Radioimmunoassay may
detect fragments of peptide giving a spuriously high result and
therefore a falsely extended half life.
Plasma ACTH and Cortisol responses to exogenous CRH are similar in
pregnant and non-pregnant women, suggesting that plasma CRHBP has
the capacity to bind additional CRH (Suda et al 1989). Although plasma
ACTH is not raised above the normal range in pregnant women, they
are still able to show activation of the HPA axis during stress.
The CRH binding protein must therefore be able to inhibit the action
of placental CRH but not hypothalamic CRH on the pituitary (Linton
et al 1990). Purified CRH-binding protein, in concentrations similar to
those found in pregnancy, was used in binding studies with CRH.
It was found that equilibrium was reached after 15 mins incubation
and it was hypothesised that acutely released hypothalamic CRH, which
is in relatively high local concentrations (lpg/1 in the rat) in the
hypothalamopituitary portal blood, exerts its effect before being bound to
CRH binding protein.
One of the major differences between man and sheep with respect to
the HPA axis is the presence of CRH BP in human plasma (but not in
sheep plasma) which binds to hCRH not oCRH (Linton et al 1988).
The half life of hCRH in man is 30 mins, which is significantly
shorter than the half life of ovine CRH in man and the half life of
both human and ovine CRH in the sheep suggesting that CRH BP
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enhances the clearance of human CRH in man. However then
mechanism of this remains unclear.
Thus, CRH BP may protect the body from the effects of the high CRH
level seen in pregnancy. The slow time course of the association of
CRH with CRH BP will still allow rapid hypothalamic pulses of CRH to
stimulate pituitary ACTH release. Recent data suggests that there may
be a marked fall in CRH BP levels in the final weeks of pregnancy
(Linton et al 1993) and this may be part of the mechanism that initiates
parturition, by allowing more free, biologically available CRH. There is
a wide normal range for plasma CRHBP, and in the first and second
trimesters this does not differ from non-pregnant levels. In the third
trimester levels are lower than in non-pregnant women, but return to
normal within 48 hours of delivery (Linton et al 1993) suggesting that
the fetoplacental unit may have an influence. In addition, pregnancies
complicated by pre-eclampsia and preterm labour show reduced levels of
CRHBP which would allow for higher plasma levels of free CRH
(Perkins et al 1992); however it is not known whether this may be only
a consequence of the disease and particularly of the associated deranged
liver function.
1.12. The control of CRH secretion by the fetal membranes and placenta.
1.12.1 Prostaglandins
Prostaglandins E2 and F2a increase in maternal and fetal plasma in late
pregnancy and during labour, and have been implicated as mediators of
the stimulation and maintenance of myometrial contractility and
cervical ripening at term. Prostaglandins stimulate the output of CRH
and ACTH in cultures of term placental cells (Petraglia et al 1987b).
The output of ACTH is itself inhibited by CRH inhibitors suggesting
that CRH may mediate this. Conversely, CRH has been seen, in short
term cultures (48hours) to stimulate prostaglandin output from amnion,
chorion, placental and decidual cell cultures obtained at term elective
caesarean section and in amnion and placental cultures of tissue from
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second trimester termination of pregnancy (Jones and Challis 1989, Jones
and Challis 1990b). The output of prostaglandins was inhibited by ACTH
antisera (Jones and Challis 1990a), thus, ACTH may have a modulatory
role in both the stimulation of prostaglandins by CRH and the
stimulation of CRH by prostaglandins. Furthermore, in early pregnancy
tissues, and in term placenta and decidua, ACTH itself stimulates
prostaglandin output (Jones and Challis 1989). In cultured amnion
cells, glucocorticoids stimulate PGE2 output in a dose dependant
manner (Potestio et al 1988), and potentiates the effect of adding the
PG precursor, arachidonic acid. It has therefore been suggested, that this
effect is secondary to increased synthesis of prostaglandin synthase. This
may be mediated through CRH since glucocorticoids stimulate CRH and
CRH stimulates prostaglandin output.
1.12.2. Steroids
Steroid hormones modulate the placental production of CRH. In short
term cultures (48 hours) of amnion, chorion and decidua, Cortisol and
dexamethasone stimulated CRH output in a dose dependent manner
(Jones et al 1989). Furthermore, in 3 day old cultures of placental cells,
dexamethasone increased CRHmRNA levels after incubation for 48
hours (Robinson et al 1988). However, when betamethasone, a long
acting steroid, was given to women in preterm labour up to 21 hours
prior to delivery no change in plasma CRH was seen although ACTH
and Cortisol levels were suppressed (Tropper et al 1987). It seems that
glucocorticoids stimulate CRH secretion by the placenta but inhibit the
HPA axis. Robinson has proposed that CRH from the placenta passes
via the umbilical vein to the fetus and stimulates ACTH secretion by
the fetal anterior pituitary. This stimulates the secretion of Cortisol by
the fetal adrenal cortex which passes back to the placenta and may act
there as a positive feedback stimulator of CRH synthesis and release.
Because glucocorticoids have an important role in the maturation of
fetal organs the CRH/ glucocorticoid positive feedback loop holds
advantages for fetal wellbeing, as well as being central to a
glucocorticoid-ACTH-CRH cascade postulated as a mechanism which
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occurs at the onset of parturition (Challis and Hooper 1989) CRH
stimulates the output of POMC peptides, ACTH (Petraglia et al 1987), a-
melanocyte-stimulating hormone and P-endorphin, in a dose dependant
fashion from placental explants in culture (Margioris et al 1988).
In contrast, in short term cultures of amnion, chorion, placenta and
decidua, progesterone inhibited CRH output (Jones et al 1989). The high
levels of progesterone in maternal plasma during pregnancy may thus
inhibit CRH output until some as yet unknown mechanism overrides
this prior to birth when the CRH level is allowed to rise. In man,
unlike the situation in the sheep, there is no fall in plasma
progesterone prior to parturition suggesting that this change may occur
at a local level.
1.12.3. Oxytocin
Oxytocin is a positive inotrope which stimulates myometrial
contractility and CRH potentiates its effects (Quatero and Fry 1989).
Preincubation of strips of myometrium with CRH primed the muscle
for the inotropic effect of oxytocin. Furthermore, CRH and oxytocin
together had a greater effect on myometrial contractility than oxytocin
alone (CRH alone has no inotropic effect) (Quatero and Fry 1989), and
this CRH potentiation of the action of oxytocin appears to be mediated
by prostaglandins, probably PGF20C (Quatero et al 1991). Recent work has
shown that the myometrium has binding sites for CRH that increase in
affinity during pregnancy and may influence parturition by sensitizing
the myometrium to oxytocin (Quatero et al 1992, Hillhouse et al 1993).
Furthermore oxytocin stimulates the release of CRH from placental cells
(Petraglia et al 1989b). It has been hypothesised therefore that during
labour release of oxytocin stimulates further production of CRH which
in turn potentiates the effects of oxytocin on myometrial contractility.
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1.12.4. Other factors
Acetylcholine, noradrenaline, oxytocin, vasopressin and angiotensin II
have also been shown to stimulate CRH production from cultured
placental cells in a dose related manner (Petraglia et al 1989b), although
the significance of this is unclear. Acetylcholine and noradrenaline also
stimulate CRH release from rat hypothalamic tissue in vitro (Rivier
and Plotsky 1986), and the presence of adrenergic and cholinergic
receptors in placental tissue (Olubadewo and Rama Sastri 1977; Divers et
al 1981) suggests these neurotransmitters may have a role in placental
endocrine regulation. Similarly, oxytocin, vasopressin, angiotensin II and
interleukin-1 increase the release of CRH from the hypothalamus
(Sapolsky et al 1987).
These findings suggest that there may be a similar mechanism for
control for placental and hypothalamic CRH release.
The cytokines interleukin 1 alpha and 1 beta also stimulate the
production of CRH from placental cells cultured for one week (Petraglia
et al 1989b, Petraglia et al 1990b). These substances are released in
response to infection and the link between infection and preterm labour
is well known. However, studies correlating CRH levels, cytokines and
preterm labour are yet to be done.
1.13. Hypothesis for the role of CRH in parturition
Thus the placenta (probably the syncytiotrophoblast) and fetal
membranes produce increasing amounts of CRH with advancing
gestation as a result of increasing CRH gene expression. CRH increases
placental ACTH production and both may affect prostaglandin output by
the fetal membranes. The maternal HPA axis is protected from high
circulating levels by CRH BP, it is not yet known if the fetal HPA axis
is similarly protected. Placental CRH may pass into the fetal circulation
in sufficient concentrations to release ACTH from the fetal pituitary,
resulting in increased plasma Cortisol and organ maturation.
Fetal Cortisol may also act to positively feedback on placental CRH
gene expression and thus CRH production, thus forming a positive
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feedback loop. In addition placental CRH may have a paracrine role in
stimulating local prostaglandin production which itself stimulates the
release of CRH forming another positive feedback loop. Finally CRH
may sensitize the myometrium to the inotropic effects of oxytocin and
potentiate its effects once labour has started. A fall in the level of CRH
BP just prior to parturition will make more bioactive CRH available for
these pathways. The ultimate result of this series of positive feedback
loops is birth (Challis and Hooper 1989).
1.14. Placental ACTH
1.14.1. ACTH background
ACTH is a 39 amino-acid peptide which is synthesised as part of a
precursor molecule POMC. Following the signal peptide, there is an N-
Terminal fragment followed by ACTH(l-39) which is followed by the p-
lipotropin sequence. ACTH(l-39) contains within it the sequences of
alpha-melanocyte-stimulating hormone (a-MSH) (1-13) and corticotropin-
like intermediate lobe peptide (CLIP) (18-39). P-lipotropin contains within
it the sequence for y-lipotropin, P-MSH and p-endorphin (Nakanishi et
al 1979) (see figurel.6).
1.14.2. Previous studies of placental ACTH secretion.
The presence and release of an ACTH like substance in the placenta
was first suggested in the 1950's with an observation that pregnancy
stimulated adrenocortical activity in a patient with Addisons disease
(Jailer and Knowlton, 1950). This was supported by the detection of
ACTH-like activity in human placental extracts (Silman and Bergmann,
1953; Assali and Hamermesz, 1954). In the rat (Knobil and Briggs 1959),
and in the rhesus monkey (Hodgen et al 1975), pregnancy reduces the
extent of adrenal atrophy that occurs in response to maternal
hypophysectomy. More importantly, even after subsequent fetectomy
(removal of the fetus but not the placenta), Cortisol levels remained
relatively high, but then fell markedly after placental delivery,
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suggesting that the placenta provides direct support for the maternal
adrenal cortex. In human pregnancy, most, though not all, studies have
found a rise in free, biologically active Cortisol as pregnancy advances
(Nolten and Rueckert, 1981; Demey-Ponsart et al 1982). Plasma ACTH
concentrations are not depressed, in fact some studies have shown a
rise (Rees et al 1975; Genazzani et al 1975; Okamoto et al 1989; Smith et
al 1990), suggesting that the increase in Cortisol is secondary to
relatively increased ACTH secretion. Rees et al (1975) also noted that the
potent synthetic glucocorticoid, dexamethasone, which readily supresses
Cortisol in non-pregnant subjects by turning off the production of ACTH,
had little effect on circulating Cortisol levels in pregnant women. Two
theories have been suggested to account for this finding; the first
postulates an ectopic source for the ACTH (such as the placenta) the
second, a resetting of pituitary and/or hypothalamic sensitivity to
negative feedback, perhaps mediated by other hormonal changes which
occur during gestation.
1.14.3. Placental ACTH concentrations
The placenta contains immunoreactive and bioactive ACTH- like activity
(Genazzani et al., 1975, Rees et al 1975: Liotta et al 1977),
immunoreactive (3- lipotropin and (3-endorphin (Nakai et al, 1984;
Odagiri et al 1979), a small (3-endorphin-like molecule (placental b-
endorphin) (Chan and Smith 1992), and immunoreactive a-MSH (Clark et
al 1978). The placenta is not merely a storage site for pituitary POMC-
derived peptides, but can actively synthesise them (Liotta and Krieger
1980). There is some disagreement as to whether ACTH concentrations
change with gestation. Concentrations reported by Liotta et al (1977),
Rees et al (1975) and Odagiri et al (1979) are essentially similar and
vary from l-4ng/g. Lower values were reported by Genazzani et al
(1975); but there was lack of parallelism in the immunoassay of
placental extract with standard ACTH. Placental ACTH concentrations
are several orders of magnitude less than that present in the anterior
pituitary, in which the ACTH concentrations are of the order of
Ipg/mg tissue. Total human pituitary content of ACTH is approximately
500pg; with a placental weight of 500g, placental content would be
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approximately 1/1000 that of the pituitary. Peptides within the pituitary
are sequestered within granules, whereas in the placenta they are not,
implying alternative secretory mechanisms other than exocytosis.
Reported placental [3-endorphin-like concentrations range from l-2ng/g
(Nakai et al 1978; Krieger et al 1980), [3-lipotropin-like concentrations
from 3-9 ng/g (Nakai et al 1978; Krieger et al 1980) and a-MSH- like
concentrations from 0.2-0.6 ng/g (Krieger et al 1980).
Immunocytochemistry has localised ACTH (Al-Timini and Fox 1986), (3-
lipotrophin and (3 -endorphin (Laatikainen et al 1987a) to the
syncytiotrophoblasts of the placenta; and in vitro studies have shown
that these cells are capable of secreting ACTH (Liotta et al 1977), and (3-
endorphin-like immunoreactivity (Liotta and Krieger 1980).
POMC mRNA has been identified in human, rat and mouse placenta
using rat pituitary cDNA probes (Cheng et al 1986). This POMC mRNA
is shorter than its pituitary counterpart due to shortening of the 5' end.
In rat placenta, POMC gene expression seems to be constitutive as the
concentration of POMC mRNA does not change during pregnancy.
1.15. Control and effects of placental POMC secretion
Both vasopressin and CRH are potent releasers of ACTH and other
POMC peptides from the anterior pituitary. CRH also stimulates the
release of ACTH from cultured placental cells in a dose dependant
manner (Petraglia et al 1987b). In addition, dibutyryl cyclic AMP
(dcAMP) produces a similar effect, but does not potentiate the action of
CRH. It has been suggested therefore, that placental CRH may regulate
placental POMC fragment release by the cAMP-dependant intracellular
messenger system and may indirectly affect placental steroidogenesis
(Petraglia et al 1990c). ACTH in turn stimulates the output of placental
CRH as well as oestradiol and progesterone secretion from placental
explant cultures (Barnea et al 1986). It may also have a role in placental
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glucose metabolism, as it increases aerobic glycolysis and oxygen
consumption.
1.16. Plasma concentrations of POMC-derived peptides and Cortisol
Both free Cortisol (Nolten and Rueckert 1981; Demey-Ponsart et al 1982)
and urinary excretion of Cortisol increases during pregnancy.
Concentrations still, however, show diurnal variation, and increase in
response to stressors such as labour (Namba et al 1980; Nolten et al
1980; Patrick et al 1980). High plasma Cortisol concentrations are
thought to result from placental ACTH.
There is considerable debate over the concentration of pro¬
opiomelanocortin derived peptides in the maternal blood.
ACTH plasma concentrations show their normal circadian variation
in pregnant subjects (Carr et al 1981). There is some question as to
whether plasma ACTH concentrations in pregnant women are
appropriately low for the somewhat elevated free Cortisol concentrations
present. Genazzani et al (1975) reported elevated plasma ACTH
concentrations throughout pregnancy. However these results are dubious
since parallelism with standard was not obtained in the
radioimmunoassay used. Rees et al (1975) demonstrated a progressive
rise in plasma ACTH concentrations during pregnancy, although most
values were in the normal range. A similar rise was noted by Carr et
al (1981), but these values were less than those seen in normal
ovulatory women. Their interpretation of this was that maternal plasma
concentrations are initially suppressed but rise progressively throughout
pregnancy. If the placenta is the source of these pepides, it may not be
subject to negative feedback by Cortisol or progesterone.
Reports of plasma levels of (3-endorphin during pregnancy also vary
between increased (Smith et al 1990; Newnham et al 1983, Chan and
Smith 1992), decreased (Aboud 1988; Raisanen 1987) and similar (Goland
et al 1981; Stark and Frantz 1983), compared to non-pregnant women.
The placenta extensively acetylates (3-endorphin and since most of the
[3-endorphin immunoreactivity is in a non-acetylated form it has been
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suggested that this is of pituitary origin (Chan and Smith 1992). The high
levels seen during pregnancy may be in response to the elevated
placental CRH concentration in plasma (Chan et al 1993). Acetylated P-
endorphin is devoid of opiate activity and placental p-endorphin is
therefore unlikely to be involved in stress-induced analgesia during
parturition. It has been suggested, that P-endorphin has an
immunological role, affecting monocyte chemotaxis (Sacerdote and
Panieri 1989), a cardiovascular effect (Furuhashi et al 1986) and a
neuroleptic effect (DeWied et al 1980) during pregnancy.
The level of a-MSH during pregnancy is also the subject of some
dispute with some studies showing a rise in the third trimester (Clark
et al 1978) and some not (Silman et al 1975).
1.17. Fetal and placental ACTH interactions.
Early reports suggested that fetal plasma ACTH and amniotic ACTH
levels throughout gestation were markedly greater than those in
maternal plasma (Winters et al 1974; Tuimala et al 1976) throughout
gestation. However, more recently, fetal blood sampling by direct
fetoscopy has enabled more accurate measurements to be made. These
have demonstrated that the levels do not differ significantly
(Economides et al 1987). The evidence for a placental source of ACTH
in the fetal circulation is only circumstantial. Exogenous ACTH does
not cross the placenta (Miyakava et al 1974; Dupouy et al 1980) but,
growth of the adrenal cortex appears to be normal in anencephalic
fetuses up to mid gestation, (Bernischke 1956) suggesting that a factor
other than fetal or maternal pituitary ACTH is responsible for support
of the fetal adrenal. It is likely that at least some of this support may
be provided by placental ACTH, as well as hCG and prolactin (Jaffe et
al 1981; Pepe et al 1988). Late in pregnancy, the placenta may also
provides trophic support for the fetal adrenal cortex. Until birth the rate
of steroidogenesis is very high (Jaffe et al 1981; Pepe and Albrecht
1990), but after delivery its size (Schulz et al 1962) and secretory activity
(Jaffe et al 1981; Pepe and Albrecht 1990) rapidly decline possibly as a
result of removal of placental support.
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1.18. Summary of placental ACTH
The human placenta can produce and release bioactive and
immunoreactive ACTH and other POMC-derived peptides throughout
gestation. There is some debate as to whether the levels of these
peptides increase or remain constant in placenta and in plasma during
pregnancy. The production of placental ACTH is under the control of
placental CRH in a paracrine manner via cAMP-dependant intracellular
messenger system. In turn placental ACTH may influence placental
steroidogenesis via the secretion of CRH, oestradiol and progesterone.
There is indirect evidence that placental ACTH may be secreted into
both the maternal and fetal circulations. There is thus clearly a
potential role for placental ACTH in directly influencing the maternal
and/or fetal hypothalamo-pituitary-adrenal axes during human
pregnancy.
1.19. The aims of this thesis
The aims of this thesis are to investigate, in detail, the ontogeny of
placental CRH production, linking placental peptide content with its
precise cellular localisation throughout gestation and then to investigate
the effects of labour, exogenous prostaglandin and antiprogestin
administration at both early and late gestation. It will then investigate
placental ACTH in the same groups of patients in terms of placental
ACTH content, exact cellular localization and POMC gene expression.
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Figure 1.3 Steroid biosynthesis in the feto-placental unit
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a) Gibbons et al (1975)
b) Khoder and Siler-Khoder (1980)
c) Osathanondh and Tulchinsky (1980)
d) McLachlan et al (1986)
e) Lee et al (1982)
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GENERAL MATERIALS AND METHODS
This chapter describes basic materials and methods which are common
to all experiments performed. The development and validation of
specific immunocytochemical and in situ hybridisation methods are
described in detail in chapters 3 and 4.
2.1.SEPHADEX CHROMATOGRAPHY
Chromatography comparing placental extracts with both standard human
ACTH and standard human CRH was performed using a sephadex
column. A Sephadex G-50 Fine (Pharmacia Fine Chemicals Uppsala
Sweden) column was carefully poured to a length of 50xlcm in a glass
column and equilibrated with ACTH assay buffer (phosphate-EDTA
buffer; Na2HP04 (63 mmol/1), EDTA (13mmol/l), pH7.4, containing
0.02% (w/v) sodium azide, 0.1% (v/v) Triton-X-100 and 250 Kallikrein
inhibitor units of aprotinin/ml (Sigma). 10 mis of 10% bovine serum
albumin solution were added to reduce non-specific binding, and the
column re-eluted with ACTH assay buffer. Blue dextran was used to
determine the void volume of the column. Standard human ACTH
was applied to the column and sixty 1ml fractions were collected at a
flow rate of 4 ml/hr. The column was flushed with ACTH assay buffer
and placental extract which had been reconstituted in ACTH assay
buffer was applied to the column in the same way, and the fractions
collected at identical flow rate. All the fractions were collected and
stored at -20°C before radioimmunoassay for ACTH.
An identical Sephadex G-50 column was used for chromatography of
CRH except that the column was equilibrated with CRH assay buffer
(0.05mol phosphate buffer /I containing O.lmol NaCL/1. 25mmol EDTA/1,
0.01% thiomersal, 0.1% Triton X-100 and 0.1% bovine serum albumin
pH7.4). Standard human CRH (Bachem lot no. WG750) was applied to
the column and sixty 1 ml fractions collected at a flow rate of 4 ml/hr.
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The column was flushed with CRH assay buffer and placental extract
which had been reconstituted in CRH assay buffer was applied and
fractions collected at an identical rate. All the fractions were collected
and stored at -20°C before radioimmunoassay for CRH.
2.2. PEPTIDE EXTRACTION AND RADIOIMMUNOASSAY
Intensity of staining in immunocytochemistry is valuable in localising
the cellular site of the antigen. It is, however, only semiquantitative
for the amount of antigen present in the cells. In order to more
accurately measure peptide content in the different groups of tissues
studied and support the findings of the immunostaining, samples of the
same tissues collected for immunostaining and in situ hybridisation
were collected, the peptide extracted and the content of both ACTH and
CRH measured by radioimmunoassay. The peptide content with
increasing gestational age, after the administration of exogenous
prostaglandins and mifepristone, and after the effects of labour was
investigated. These results were then compared with the
immunostaining and in situ hybridisation results so that information
would be available about both gene expression and the translated gene
product in terms of both locality and quantity.
A human ACTH radioimmunoassay available within the unit was
used to measure ACTH in both extracted placenta and membranes and
in the column fractions produced after chromatography of placental
extracts and standard human ACTH (see section 4.1). Because of
problems encountered in setting up a human CRH radioimmunoassay,
a hCRH RIA kit was purchased and used to quantify CRH in the
placental extracts. To reduce expense, an ovine CRH radioimmunoassay
was used to detect CRH in column fractions of placental extracts and
hCRH standard. There is sufficient cross-reactivity between the two
species to find the retention time of hCRH standard of the column,
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and it was not necessary to accurately measure the absolute amount of
peptide in each fraction.
2.2.1. Peptide extraction
The tissues collected were those as detailed in section 2.2.1.
Immunocytochemistry. All tissues were placed, within 30 minutes of
delivery into liquid nitrogen to preserve peptide content and were
stored in liquid nitrogen until needed.
Frozen pieces of tissue were quickly weighed and then added to a
known volume of hot acid (0.1M HC1, 1.0M Acetic acid 1:1 vol/vol)
and boiled for 5 minutes. The samples were cooled on ice and
homogenised. At this point, an aliquot of each was removed and stored
at 4°C for later protein estimation. The samples were then centrifuged
at 10,000G for 30 minutes, the supernatant removed, and lyophilised in
aliquots for radioimmunoassay and chromatography.
2.2.2. Protein estimation
Protein content of the homogenised placentas was assayed using a
Bio-rad protein assay. This is a colorimetric assay for measuring total
protein concentration and is performed as follows;
The samples were treated overnight with 1M NaOH. The next day, a
2mg/ml solution of bovine serum albumin was made as a standard
and dilutions between 15 and 2000fig/ml made by diluting this in 1M
NaOH. 20gl of each solution was pipetted into a 96 well flat bottomed
plate giving dilutions ranging from 0 to 40|ig per well. Samples were
added to the plate in duplicate. lOOpl of Bio-rad protein reagent was
added to the standard curve and samples and the plate was read at O.D
260nm. The standard curve was plotted on an Apple Macintosh
computer using Cricketgraph and the straight part of the curve used to
calculate the protein concentration of the samples.
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2.3. Radioimmunoassay procedures
1. Ovine CRH radioimmunoassay
2. Human CRH radioimmunoassay kit (Penninsula laboratories)
3. Human ACTH(l-39) radioimmunoassay
2.3.1. Ovine CRH radioimmunoassay
Immunoreactive CRH from the sephadex chromatography fractions was
determined by an ovine CRH radioimmunoassay (Brooks and Challis
1988) as follows;
The radioimmunoassay was performed in plastic tubes using CRH assay
buffer (0.05 mol phosphate/1 containing 0.1 mol NaCl/1, 25mmol EDTA/1
0.01% thiomersal, 0.1% triton-X-100 and 0.1% bovine serum albumin
(Sigma chemical company) at pH 7.4). All standards, antibody and tracer
were made up in this buffer. Rabbit-ovine CRH antiserum was used at
a dilution of 1:100,000. Synthetic ovine CRH (tyr- CRH Bachem inc) was
iodinated by the chloramine-T method as follows. 4fig of Tyr-OCRH in
10|il 0.1 mol acetic acid/1, 10pl 0.5mol phosphate buffer/1 (pH7.4) and
lOpl (lmCi) Na 12$l were mixed in a plastic eppendorf tube. lOfig of
chloramine-T (lg/1) in 0.5 mol/1 phosphate buffer was added and after 15
seconds the reaction was stopped by the addition of 25pl of sodium
metabisulphite (lg/1) in phosphate buffer. The mixture was then applied
to a Sep-Pak Ci8 cartridge (Waters Associates, Milford M.A. U.S.A)
which had been pre-wetted with 5ml methanol followed by lOmls of
distilled water. Free iodine was eluted in 6mls 0.05mol phosphate
buffer/1 containing 0.1% trifluoroacetic acid (TFA) and 125i_iabelled Tyr-
oCRH was then eluted in 3mls of a mixture of acetonitrile (80%) and
phosphate buffer (0.05 mol/1) containing 0.1% TFA (20%). Tracer was
stored at 4°C. Before use in a radioimmunoassay, the binding of tracer
to CRH2G antiserum was checked.
The assay standards (0.1ml) (in triplicate ) and the unknown samples
(0.2ml) (in duplicate ) were incubated overnight at 4°C, with CRH2G
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antibody(O.lml) at a dilution of 1:100,000. Then approximately 10,000 cpm
of tracer (0.1ml) (125i_0crj-q was added and the mixture incubated for a
further 24 hours. Free and bound steroid was separated by incubation
with Magsep particles (donkey-anti rabbit seond antibody attached to
magnetic particles kindly supplied by Dr R Kelly, MRC Reproductive
Biology Unit Edinburgh). The detection limit of the assay is 10-15
pg/tube.
The CRH2G antibody shows minimal cross-reactivity (<0.001%) with a
number of other hypothalamo-pituitary peptides including ACTH (1-39),
ACTH (1-24), (3-endorphin, a-melanocyte-stimulating hormone, met-
enkephalin, leu-enkephalin, arginine vasopressin, oxytocin, thyrotrophin-
releasing hormone and luteinizing hormone-releasing hormone.
Bound radioactivity was measured using a multigamma counter (1261
Multigamma, LKB Wallac OY, Turku, Finland), from which the output
of the raw counts was recorded by a digital data logger (Data grabber,
Mutek, Box, Wiltshire) onto a floppy disc. The data was then transferred
from the data grabber disc onto an Apple Macintosh computer where
raw counts were assayed by the AssayZap universal assay calculator
program (Elsevier, Biosoft, UK). A four parameter weighted-regression
model of a displacement curve was used for this program. This begins
with the two-parameter logit-log model as a first estimate, but then
adjusts the asymptotes, slopes and points of inflection (the four
parameters) of model curve reiteratively, in order to give more weight
to the standard points with smaller variance, until optimum squares fit
is obtained. Assayzap also preserves previous information of assay
history in order to compare with previous standard curves, quality
control and binding level.
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2.3.2. Human CRH radioimmunoassay kit
Because of the low titres of human CRH antibody raised in house, it
was decided to purchase a human CRH radioimmunoassay kit
(Peninsula laboratories, inc Belmont California USA). The asaay was
performed following the manufacturers instructions. Briefly, all reagents
were prepared in assay buffer supplied with the kit. The lyophilised
placental extracts were reconstituted in assay buffer, and 0.1ml volumes
were incubated overnight at 4°C with antiserum (rabbit anti human
CRH). The next day, 0.1ml of tracer were added (10,000 cpm) and the
mixture incubated for a further 24 hours at 4°C. Separation of bound
and free CRH was achieved by addition of 0.1ml of goat antirabbit IgG
serum, and 0.1ml of normal rabbit serum. The tubes were mixed and
the contents incubated for 90 minutes. The samples were centrifuged at
3,000r.p.m for 20 minutes at 4°C and the supernatant aspirated.
A standard curve was set up and run in parallel with the samples.
Bound radioactivity was measured using a multigamma counter as for
oCRH assay. The standard curve and unknown samples were calculated
using AssayZap as for oCRH assay. The limit of sensitivity of this assay
is 1 pg/tube.
2.3.3. Human ACTH radioimmunoassay
The concentration of ACTH in both placental extracts and in column
fractions from chromatography comparing placental extract with standard
ACTH was determined by double antibody radioimmunoassay using a
human ACTH antibody elaborated by Dr A.F. Parlow (AFP6328031)
(Director of The Pituitary hormones and Antisera centre Torrance , CA,
USA) and supplied by the National Institute of Diabetes & Digestive &
Kidney Diseases (NIDDK). Synthetic ACTH (1-39) for use as a standard
and for iodination was purchased from Cambridge Research
Biochemicals. Iodinated ACTH was prepared using the chloramine-T
method and separated using Sephadex G-50 Fine chromatography.
Lyophilised placental extracts were reconstituted in ACTH assay buffer
(Na2HP04(63mmol/l), EDTA (13mmol/l), pH7.4) containing 0.02% (w/v)
sodium azide, 0.1% (v/v) Triton-X-100 and 250 Kallikrein inhibitor units
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of aprotinin/ml (Sigma, Dorset UK). Column fractions were assayed
directly. Samples (0.1ml), in duplicate, were incubated overnight at 4°C
with ACTH antiserum (at a final dilution of 1:12,500). Iodinated ACTH
(approximately 15,000 cpm) (0.1ml) was added to all tubes and incubated
for a further 24 hours. Standards, antibody and tracer were all diluted
in ACTH assay buffer. Free and bound ACTH was separated by
incubation with Magsep particles (donkey anti rabbit second antibody
attached to magnetic particles, kindly supplied by Dr R Kelly MRC
Reproductive Biology Unit Edinburgh). Bound radioactivity was
measured using a Multigamma 1261 counter (see oCRH RIA). Standard
curve samples were prepared in ACTH assay buffer and assayed
simultaneously and used to calculate the concentration of ACTH in the
unknown samples. The limit of sensitivity of this assay is l.Opg/tube.
The antibody used for this assay is highly specific for ACTH (1-39)
having minimal cross-reactivity for ACTH(l-lO), ACTH(ll-24), ACTH (1-
24), and a-MSH.
All the results of ACTH and CRH content of placental extracts were
expressed in terms of the protein content of the tissues.
2.4. Statistical Analysis
All statistical analysis was performed on an Apple Macintosh computer
using the Statworks program (Data Metrics Inc., U.S.A). Two way
analysis of variance comparing placental ACTH or CRH content with
gestational age, and comparing different tissue types and different modes
of delivery was assessed by analysis of variance using a statistics
program written for the Apple Macintosh Computer (CLR Anova, Clear
Lake Research Houston Texas USA).
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CHAPTER 3
DEVELOPMENT OF IMMUNOCYTOCHEMICAL METHODS TO




Immunocytochemistry is a very sensitive and specific method, using
antibody-antigen complexes tagged by a visible label, to allow
visualisation, in situ, of a wide variety of cell products. In early
immunocytochemical methods, the specific antibody itself was labelled
(the direct method) but indirect methods tend to be more sensitive
and are now commonly used. In the development of
immunolocalisation methods for this thesis both avidin-biotin and
antibody-enzyme bridge techniques were used. Indirect methods
involve the application of the primary, unlabelled, antibody to the
section. A second, labelled, antibody from another species, raised to
the IgG of the animal donating the first antibody, is then applied, the
first antibody acting as an immunoglobulin antigen. Label intensity is
significantly enhanced with this method compared with the direct
method. The reasons for this are not clear. The primary antibody
molecule may bind several molecules of the second, labelled,
antibody, or the hyperimmunity and therefore higher titre of the
second antibody may be responsible. Avidin has a very high affinity
for biotin, one molecule being able to bind four molecules of biotin.
Biotin will also bind the Fc portion of immunoglobulins, each also
able to bind several molecules of biotin. Both avidin and biotin may
be labelled and with the right combination of avidin, biotin and
antibody it is possible to build up very high concentrations of label
thus increasing the sensitivity. The avidin-biotin method is known to
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produce a high level of sensitivity with paraffin embedded sections.
Both the methods described in this thesis involve the use of
antibodies and the enzyme peroxidase. The use of peroxidase as an
enzyme has several advantages including its stability, wide
availability, cost and the ability to easily quench endogenous tissue
peroxidase activity (see section 3.2.5.). For the avidin-biotin method,
three reagents are used; a primary antibody specific for the antigen to
be localised, a secondary antibody capable of binding to the first
which is conjugated to biotin, and a complex of peroxidase conjugated
avidin and biotin. The free sites of the avidin molecule allow
binding to the biotin on the secondary antibody. The peroxidase
enzyme and therefore the original antigen are visualised with an
appropriate chromagen. The strong affinity of avidin for biotin gives
this method great sensitivity.
Unlabelled antibody-enzyme bridge techniques utilise a bridging
antibody (unconjugated) between the primary antibody and the final
antibody. The final antibody is also unconjugated and raised to
horseradish peroxidase in the same species as the primary antibody.
This layer is followed by horseradish peroxidase which is then bound
by an antigen-antibody reaction and can then be developed.
The avoidance of chemical conjugation means that the
immunological reactivity of all the antibodies is kept to a maximum.
Optimal specific staining depends not only on the characteristics of
the primary antibody and the antigen to be localised but also
appropriate tissue fixation and preparation, the optimal dilution of
primary and secondary antibodies, incubation times and temperatures.
These conditions were investigated in order to achieve reproducible
specific staining with minimal background staining. Positive staining
of a specimen not a result of antigen-antibody binding is termed non¬
specific staining. The main causes of this and their solutions are
considered in detail in section 3.2.5.
44
3.2 Materials and methods
3.2.1 Tissue Collection
All gestations were calculated from the date of the last menstrual
period and confirmed by ultrasound and/or clinical assessment.
Decidual and trophoblastic tissues were obtained from patients
undergoing therapeutic surgical termination of pregnancy in the first
trimester for social reasons by suction curettage, with or without
pretreatment with the synthetic prostaglandin analogue gemeprost
(16,16 dimethyl transA2 PGEi methylester) between 2 and 4 hours
prior to the procedure. Tissues were also obtained from patients
undergoing medical therapeutic termination of pregnancy for social
reasons in the first and second trimester using mifepristone 600mg
orally 48 hours prior to receiving a lmg gemeprost vaginal pessary.
All patients aborted within 6 hours. Placenta and fetal membranes
were also collected from spontaneous vaginal deliveries preterm
(between 24-35 weeks gestation, at term (36-42 weeks gestation) by
elective caesarean section, spontaneous vaginal delivery, and by
induction of labour using prostaglandin E2 (all patients studied
recieved 2mg of PGE2 and all delivered within 24 hours). There was
no clinical evidence of infection such as pyrexia in any patient, nor
any histological evidence of neutrophil infiltration in any tissue
studied. For immunocytochemistry, all tissues were divided into
blocks of approximately 1.5cm3 and placed in 4%(w/v) buffered
paraformaldehyde (pH 7.4) within 30 mins of delivery.
3.2.2 Tissue Fixation Time
The optimal fixation time of the cross-linking fixative, 4%
paraformaldehyde was evaluated over the range 8-48 hours.
After fixation tissue was processed through graded ethanol in a
standard tissue processor and embedded in paraffin wax. The paraffin
wax blocks were stored in a cool place.
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3.2.3 Tissue Pretreatment
Tissue sections of 5(im were cut on a microtome and floated onto
clean glass slides and baked overnight at 56°C. To facilitate tissue
penetration by the antibody, the slides were pretreated with
0.1% (w/v) trypsin (Type III from bovine pancreas, Sigma Chemical
Company, Dorset) and the optimal incubation time and temperature
was evaluated. The slides were also washed in 0.5% (v/v) Triton-X 100
before application of the primary antibody.
3.2.4 Antibodies
3.2.4.1. CRH immunostaining
The primary antibody used for CRH immunostaining was a
polyclonal CRH antisera raised in rabbits against an ovine CRH-
thyroglobulin conjugate (CRH2G kindly supplied by Dr A.N. Brooks)
The secondary antibody used for CRH immunostaining was
biotinylated swine anti-rabbit immunoglobulin G (DAKO E353 Lot no.
053)
A checkerboard titration was used to determine the optimal dilution
of both primary and secondary antibody.
Primary antibody








The primary antibody used for ACTH immunostaining was a
polyclonal anti CLIP antiserum raised in a rabbit which shows 100%
cross-reactivity with ACTH (kindly supplied by Professor L. Rees St
Bartholomew's Hospital London).
Two different staining methods were used to stain for ACTH:
1. An avidin-biotin method similar to that used for CRH
immunostaining using biotinylated swine anti-rabbit
immunologlobulin G as the secondary antibody and avidin biotin
complex.
2.An alkaline phoshatase anti alkaline phosphatase bridge technique
with nitroblue tetrazolium as the chromagen. The linking antibody
used was a swine anti rabbit immunoglobulin G (DAKO Z196 Lot
no.022)The secondary antibody used was alkaline phosphatase anti
alkaline phoshatase (DAKO D651Lot no.091)
The optimal dilution of primary and secondary antibody for the





The dilutions of linking antibody and secondary antibody were
determined using a checkerboard.
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3.2.5 Non-specific background staining
Non-specific background staining is staining of a specimen not due to
antigen-antibody binding. The most common cause is attachment of
antibody to highly charged collagen and connective tissue elements of
the tissue. In addition, the substrate-chromagen reaction used to
visualise peroxidase cannot distinguish between the enzyme
immunologically localising the cellular antigen and similar enzymatic
activity present in the specimen before staining. This is especially
problematic in tissues such as placenta that contain a lot of red blood
cells. If this endogenous peroxidase activity is not removed before
adding the marking enzyme non-specific background staining will
occur.
The following steps were taken to eliminate background staining:
1. Inhibition of endogenous peroxidase activity by incubating the
sections for 30 mins at room temperature in a solution of 3% (v/v)
hydrogen peroxide in 100% methanol.
2.Reduction of ionic interaction of tissue with antibody by addition of
0.9% NaCl in 0.05% M Tris /HC1 buffer (Tris Buffered Saline, TBS. See
Appendix 5)
3.The use of a blocking solution of 25%(v/v) normal swine serum




The following negative controls were used; CRH primary antibody
was substituted by antibody dilution buffer, non-immunised rabbit
serum (1:100) dilution or CRH antibody (1:1000) dilution that had been
preabsorbed for 18 hours at 4°C with 5|iM human CRH (Bachem
(UK)Ltd Saffron Walden Essex). The positive control used in each
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case was term placenta (previously shown to stain positvely for CRH
using this antibody by Riley et al 1991).
3.2.6.2. ACTH immunostaining
The following negative controls were used; anti CLIP antibody was
substituted by antibody dilution buffer, non-immunised rabbit serum
or anti-CLIP antibody (1:1000) that had been preabsorbed overnight
with 5pM human ACTH for 18 hours at 4°C. The positive control
used in each case was adult sheep pituitary.
3.3 Results and Discussion
3.3.1 Fixation
The results of immuncytochemistry can only be as good as the tissue
used. It is therefore of great importance that the tissue is correctly
fixed and processed and that the antigen being localised is not only
fixed, but also available and accessible to the primary antibody. One of
the most commonly used fixatives for immunocytochemistry of
paraffin-embedded sections is paraformaldehyde. Due to its cross-
linking properties it is especially good for fixing small molecules such
as hormones. However fixation time is critical to prevent antigen
masking . Small blocks of tissue (maximum 2cm^) should be placed in
a minimum of 200 mis of formaldehyde. The formaldehyde used was
buffered to pH 7.4 as acidic solutions can cause structural disturbances
and poor morphology.
A phosphate buffer was used to make up the formaldehyde to
maintain tonicity. Early and term placentas were fixed for 8 hours,
22 hours and 48 hours in 4% buffered paraformaldehyde, providing a
wide range of fixation times including that already used for tissues of
this type in this laboratory. In 8 hours insufficient fixative had
permeated the tissue, it was too soft to be sectioned and its
morphological integrity was destroyed. In contrast, tissue fixed for
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48 hours showed no positive immunostaining even after a trypsin
digestion stage. The optimum fixation time was found to be 22 hours
and subsequently all tissues were left at room temperature for this
time before processing, (see plate no. 3.1)
3.3.2. Tissue pretreatment
As described above, fixation time is critical to prevent antigen
masking. Formaldehyde forms cross linkages with basic amino acids,
mainly lysine and arginine hindering penetration by antibody.
Treatment with trypsin can digest these excess linkages and expose
the antigen. To improve staining a trypsin digestion stage was added
to the protocol. The times and temperatures to which the sections
were exposed to trypsin were determined. Slides were incubated for 15
minutes, 30 minutes and
1 hour at 37°C and room temperature. In all cases, a 0.1% (w/v)
Trypsin (Type III from bovine pancreas Sigma Chemicals Poole
Dorset) solution in 0.1% CaCl2 was used. It was found that a
30 minute incubation at 37°C gave the strongest specific staining,
with minimal background. The 15 minute digestion did not improve
the staining intensity, and the 1 hour digestion caused an
unacceptable level of background staining. (See plate 3.1)
In addition to trypsin digestion, washing the section with a solution
of Triton-X 100 is known to improve tissue permeability to antigen
by solubilising the lipid component of the cell membrane. Therefore,
a 15 minute wash of a 0.5% solution of Triton-x was added to the
protocol.
3.3.3. Antibodies
The optimal dilution to be used depends on a number of different
factors:
In polyclonal serum such as that used for both the CRH and ACTH
immunostaining high levels of substances other than the specific
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antibody will be present. This necessitates high dilutions to prevent
non-specific background staining.
Generally, the longer the incubation time, the more dilute the
antibody can be used.
As mentioned above, the fixation time, tissue processing and
pretreatment protocol, including trypsin digestion, all affect optimal
antibody dilution.
In both the CRH and ACTH staining methods, the antigen is
localised via a system involving more than one antibody. The
concentrations of both antigens are critical to the success of the
system. The outcome should be the greatest possible intensity of
staining with the lowest possible background.
3.3.3.1. CRH immunostaining
The optimal primary antibody dilution was found to be 1:1000. The
biotinylated swine anti rabbit immunoglobulin G was used at a
dilution of 1:500. (See Plate 3.2. for primary and secondary antibody
dilutions.)
3.3.3.2. ACTH immunostaining
Two different methods were tried to achieve the best specific staining
of ACTH within the tissues. The first was an avidin-biotin method
such as that used for the CRH immunolocalisation. Unfortunately
this did not produce the intensity of staining seen for CRH.
Presumably this was due to the much smaller quantities of ACTH
present. The avidin-biotin method with DAB as a chromagen gives a
very specific result but tends to produce a fainter stain. It was
therefore decided to try an alkaline phosphatase anti alkaline
phosphatase bridge technique using nitroblue tetrazolium as the
chromagen. (See Plate 3.3 for the results of staining using both
techniques). This bridge technique uses alkaline phosphatase as a
central part. The placenta contains a large quantity of endogenous
alkaline phosphatase and it might be expected that this would result
in problems with non-specific background staining. However, the
staining was seen to be consistently localised to the same cells and
no staining was seen in the preabsorbed controls suggesting specific
staining.
3.3.4. Controls
In both the CRH immunostaining and the ACTH imunostaining,
there was no specific staining where primary antibody was substituted
for by antibody dilution buffer, non-immunised rabbit serum or
primary antibody that had been preabsorbed ar 4°C for 18 hours with
5jiM human CRH (in the case of CRH immunostaining), or
5(iM ACTH (in the case of CLIP immunostaining) (See plates 3.2 and
3.3). In contrast specific immunostaining was seen in the positive
controls. These results confirm that both the CRH immunostaining
method, and the CLIP immunostaining method were specific.
3.4. Conclusion
The optimal immunostaining methods were therefore as follows
3.4.1. CRH Immunostaining
5jim sections were cut, floated onto microscope slides and then
baked overnight at 56°C. The next day they were deparaffinised in
xylene substitute (Histoclear, National Diagnostics New Jersey) and
rehydrated in graded ethanol. The sections were incubated for
30 minutes in 3% (v/v) hydrogen peroxide (BDH chemicals Ltd, Poole
Dorset, U.K.) in methanol (BDH) to block endogenous peroxidase
activity, then washed in 0.05M Tris-HCl buffer (TBS; 0.05M
Tris(hydroxymethyl)methylamine/l; 0.9% (w/v) NaCl, pH 9.6) twice for
5 minutes, The sections were then incubated with 0.1% Trypsin (Type
III from bovine pancreas, Sigma Chemical Company Poole Dorset) in
0.1%(w/v) CaCl2 (BDH) pH7.4 at 37°C for 30 mins to facilitate
penetration of the tissue by the antibody and then washed twice for
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5 minutes in TBS before a wash in 0.5% (v/v)Triton-X 100 in distilled
water for 15 minutes. After two 5 minute washes in TBS, sections
were incubated with 25% (v/v) normal swine serum and 5% (w/v)
bovine serum albumin in TBS for 30 minutes at room temperature
to reduce non-specific staining. Sections were then incubated overnight
at 4°C with primary antibody in a humidified chamber. The sections
were then washed twice in TBS for 5 minutes and then incubated for
30 minutes with secondary antibody, biotinylated swine anti-rabbit
immunoglobulin G (DAKOPATTS, DAKO Ltd) diluted (1:500) in
TBS/NSS/BSA. Following two further washes in TBS for 5 minutes,
peroxidase-conjugated avidin-biotin complex (DAKOPATTS, DAKO
Ltd) was applied according to the manufacturers instructions for
30 minutes. The sections were then twice washed in TBS for
5 minutes. Hormone was localised by the detection of peroxidase
activity, effected by a 5 minute incubation with a freshly prepared
solution containing 3,3-diaminobenzidinetetrachloride (DAB 0.4mg/ml
0.05M Tris-HCl) to which was added 0.01% hydrogen peroxide.
Sections were counterstained with haematoxylin, dehydrated through
graded ethanol, cleared in xylene and mounted in Eukitt (Kindler.
Gmbh+Co Freiburg Germany) for microscopic examination.
3.4.2. ACTH immunostaining
5|im sections were cut, deparaffinised in xylene substitute (Histoclear,
National Diagnostics, New Jersey) and rehydrated in graded ethanol.
The sections were washed in 0.5 M Tris-HCl buffer (TBS; 0.5 mol
Tris(hydroxymethyl)methylamine; 0.9% NaCl (w/v) (pH 7.6) for
10 mins and then incubated with 0.1% Trypsin (Type III from bovine
pancreas, Sigma chemical company Dorset) in 0.1% (w/v) CaCl2 (BDH)
pH 7.4 at 37°C for 30 mins to facilitate penetration of the tissue by
the antibody and then washed for a further 10 mins in TBS before a
wash in 0.5% Triton-X-100 (vol/vol) in distilled water for 15 mins.
After two 5 min washes in TBS, sections were incubated with
25%(vol/vol) normal swine serum and 5% bovine serum albumin in
TBS for 30 mins at room temperature to reduce non-specific staining.
Sections were then incubated overnight with primary antibody at a
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dilution of 1:1000 at 4°C in a humidified chamber. The sections were
then washed twice in TBS for 5 mins and then incubated for
30 mins with secondary antibody swine antirabbit immunoglobulin G
(DAKOPATTS, DAKO Ltd) diluted (1:60) in TBS/NSS/BSA. Following
two further washes in TBS for 5 mins the sections were incubated
for a further 30 mins with alkaline phosphatase anti-alkaline
phosphatase antibody diluted (1:100) in NSS/TBS/BSA. The sections
were then washed twice in TBS and then once in TBS/MgCl2
(lOOmM tris pH 9.5, 50mM MgCl2, lOOmM NaCl). Substrate solution
was then added (10 mis Tris/MgCl2 pH 9.5, 45jil NBT, 35|il
X-phosphate, lOpl levimasole) The slides were then incubated in the




Plate 3.1. Development of an immunocytochemistry method to
localise human corticotrophin releasing factor within the placenta
and fetal membranes.
3.1.A. Immunolocalisation of CRH in human placenta fixed for 48
hours in 4% paraformaldehyde. Predigestion with 0.1% (w/v)
trypsin was performed on the sections and the primary and
secondary antibodies were used at 1:1000 and 1:500
respectively.
3.I.B. Immunolocalisation of CRH in human placenta fixed for 22
hours in 4% paraformaldehyde. Predigestion with 0.1% (w/v)
trypsin was performed on the sections and the primary and
secondary antibodies were used at 1:1000 and 1:500
respectively. Note the increased intensity of staining
compared with 3.1.A.
3.l.C. Immunolocalisation of CRH in human placenta fixed for 22
hours in 4% paraformaldehyde. Predigestion with 0.1% (w/v)
trypsin was performed at room temperature for 15 minutes
on the sections and the primary and secondary antibodies
were used at 1:1000 and 1:500 respectively.
3.I.D. Immunolocalisation of CRH in human placenta fixed for 22
hours in 4% paraformaldehyde. Predigestion with 0.1% (w/v)
trypsin was performed at 37° C for 30 minutes on the
sections and the primary and secondary antibodies were used
at 1:1000 and 1:500 respectively. Note the increased
immunostaining compared to 3.l.C.
The bar indicates 50|im
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Plate 3.2. Determination of optimal primary and secondary antibody
concentration for CRH immunostaining
3.2.A. Immunolocalisation of CRH in human placenta fixed for 22
hours in 4% paraformaldehyde. Predigestion with 0.1% (w/v)
trypsin was performed on the sections and the primary and
secondary antibodies were used at 1:500 and 1:500
respectively. Note the very high level of non-specific
staining.
3.2.B. Immunolocalisation of CRH in human placenta fixed for 22
hours in 4% paraformaldehyde. Predigestion with 0.1% (w/v)
trypsin was performed on the sections and the primary and
secondary antibodies were used at 1:1500 and 1:200
respectively. Note the faint staining.
3.2.C. Immunolocalisation of CRH in human placenta fixed for 22
hours in 4% paraformaldehyde. Predigestion with 0.1% (w/v)
trypsin was performed on the sections and the primary and
secondary antibodies were used at 1:1500 and 1:500
respectively. Note the faint staining.
3.2.D. Immunolocalisation of CRH in human placenta fixed for 22
hours in 4% paraformaldehyde. Predigestion with 0.1% (w/v)
trypsin was performed on the sections and the primary and
secondary antibodies were used at 1:1000 and 1:200
respectively.
3.2.E. Immunolocalisation of CRH in human placenta fixed for 22
hours in 4% paraformaldehyde. Predigestion with 0.1% (w/v)
trypsin was performed on the sections and the primary and
secondary antibodies were used at 1:1000 and 1:500
respectively. Note the specific staining of the
syncytiotrophoblast with minimal background staining.
3.2.F. Control tissue. Human placenta fixed for 22 hours in 4%
paraformaldehyde. Predigestion with 0.1% (w/v) trypsin was
performed on the sections. The secondary antibody was used
at 1:500. The primary antibody at a dilution of 1:1000 had
been preabsorbed overnight at 4°C with 5(iM human CRH.
The bar indicates 50pm
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Plate 3.3. Determination of optimal conditions for the
immunolocalisation of ACTH in human placenta and fetal
membranes. (The bar indicates 50jim)
3.3.A Avidin-biotin immunolocalisation of ACTH in human
placenta. Predigestion with 0.1% (w/v) trypsin was
performed on the sections and the primary and secondary
antibodies were used at 1:500 and 1:500 respectively.
3.3.B. Avidin-biotin immunolocalisation of ACTH in human
placenta. The primary and secondary antibodies were used at
1:200 and 1:500 respectively. Note the low level of
generalised non-specific staining. It was therefore decided to
use an alkaline phosphatase anti alkaline phosphatase
bridging technique.
3.3.C. Immunolocalisation of ACTH in human placenta using the
APAAP method. Predigestion with 0.1% (w/v) trypsin was
performed on the sections and the primary and secondary
and APAAP antibodies were used at 1:500 and 1:60 and
1:100 respectively.
3.3.D. Immunolocalisation of ACTH in human placenta as in 3.3.C
The primary and secondary and APAAP antibodies were
used at 1:1500 and 1:60 and 1:100 respectively.
3.3.E. Immunolocalisation of ACTH in human placenta as in 3.3.C.
The primary and secondary and APAAP antibodies were
used at 1:1000 and 1:60 and 1:100 respectively.
3.3.F. Immunolocalisation of ACTH in human placenta as in 3.3.C.
The primary and secondary and APAAP antibodies were
used at 1:2000 and 1:60 and 1:100 respectively.
3.3.G. Positive control. Immunolocalisation of ACTH in adult
sheep pituitary as in 3.3.C. The sections and the primary
and secondary and APAAP antibodies were used at 1:1000
and 1:60 and 1:100 respectively.
3.3.H. Negative control. Immunolocalisation of ACTH in human
placenta as in 3.3.C. The sections and the primary and
secondary and APAAP antibodies were used at 1:1000 and
1:60 and 1:100 respectively. The primary antibody was
preabsorbed overnight with 5pM human ACTH.
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CHAPTER 4
DEVELOPMENT OF IN SITU HYBRIDISATION METHODS TO




In situ hybridisation techniques allow specific nucleic acid sequences to
be detected in individual cells. The development of in situ hybridisation
methods, in combination with the immunocytochemical techniques
developed in chapter 3 for CRH and ACTH would allow both the
mRNA transcribed from the gene itself and the gene product translated
from the mRNA to be identified.
The technique was originally developed in the 1960s (Pardue and Gall
1969; John et al 1969; Buongiorno-Nardelli and Amaldi 1969) and was
used primarily for the localisation of DNA sequences. More recently it
has been used in the detection of specific mRNA sequences as well as
for chromosomal gene mapping.
A probe is a nucleic acid sequence of either DNA or RNA, labelled by
incorporation with either a radioactive or non-radioactive marker. The
single stranded probe hybridises (anneals) to its complementary single-
stranded nucleic acid sequence in the tissue section to form a new
double stranded molecule that incorporates the label. The sites of
hybridisation are then detected and visualised. The detection method
depends on the nature of the reporter molecule, which may be
radioactive or non-radioactive. Both DNA and RNA probes can be used
to detect mRNA and hence gene expression in tissue sections, but
DNA probes are more commonly used as they are less susceptible to
degradation. The best probe length for in situ hybridisation is about
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100-300 bases, for optimal nucleic acid hybrid stability and tissue
penetration. DNA probes may be produced by cloning and purification
of any DNA sequence using recombinant technology, or oligonucleotide
sequences can be synthesised de novo. Probes produced by both these
methods were used in the development of the in situ hybridisation
techniques described in this chapter. To clone nucleic acids, the DNA is
inserted into a vector, commonly a plasmid, and amplified in
appropriate host cells. For RNA probes (riboprobes) the sequence of
interest is inserted into a vector containing transcription initiation sites
for bacteriophage RNA polymerases. These sites enable transcription to
be initiated in vitro in the presence of labelled and unlabelled
nucleotides as substrates. This method was used in the in situ
hybridisation method for the detection of POMC mRNA (see section
3.2.3.3.). Riboprobes tend to form more stable hybrids than do
oligonucleotides because of their much longer length, however this may
impede tissue penetration. Synthetic oligonucleotides are sequences of
nucleotides usually 10-50 base pairs long which are synthesised on a
DNA synthesiser. They are usually labelled by an end labelling reaction
such as that described in section 4.2.3.1. and appendix 3. The short
length of oligonucleotide probes has the advantage of good tissue
penetration, but even a few mismatched base pairs will significantly
reduce the stability of the nucleic acid hybrids.
The sensitivity of in situ hybridisation depends on the effect of tissue
preparation on retention and accessibility of cellular (target) DNA or
RNA; the type of probe construct, efficiency of probe labelling and
sensitivity of the method used for signal detection; the effect of
hybridisation conditions on the efficiency of hybridisation. In developing
an in situ hybridisation method, all these factors must be taken into
consideration.
The aim of this study was to develop an in situ hybridisation method,
using an oligonucleotide probe to CRH mRNA and a riboprobe to
POMC mRNA, to investigate the cellular localisation of the respective
mRNA within the placenta and fetal membranes. The technique would
then be used to see if gene expression and/or histological distribution
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was affected by gestational age, administration of exogenous
prostaglandins or the antiprogestin mifepristone, or by labour.
4.2 Materials and Methods
4.2.1. Collection and Fixation of Tissue
The tissues were collected and fixed as for the immunocytochemistry
studies. See Section 3.2.1- 3.2.2. Development of an immunocytochemical
method to localise CRH and ACTH within the placenta and fetal
membranes.
The fixed tissue was processed on a standard tissue processor and
embedded in parrafin wax. 5pm sections were cut on a microtome
using a clean blade that had been dipped in xylene to avoid RNAse
contamination and then floated onto TESPA-coated (to improve
adherance of the sections) slides (see Appendix 1. for details of
preparation of TESPA coated slides) and then baked overnight at 56°C.
4.2.2. Tissue pretreatment
(All solutions used for in situ hybridisation are detailed in Appendix 2.)
Sections were dewaxed in xylene for 10 minutes and then rehydrated in
clean, graded ethanol. They were then pretreated with 0.2M HC1 for 20
minutes at room temperature before two 5 minute washes in Stillplus
water. Thereafter they were incubated at 37°C for 30 minutes in 2pg/ml
proteinase K. After a wash in 0.2% glycine for 20 minutes they were
washed in TEA before acetylation with acetic anhydride.
63
4.2.3. Probes
4.2.3.1. Oligonucleotide probe specific for human CRH mRNA labelled
with Digoxigenin.
Three synthetic oligodeoxyribonucleotides (two antisense and a sense
probe, for sequences see figure 4.1.) were made on a 391 DNA
Synthesizer (Applied Biosystems PCR-MATE). The sequences were chosen
from the full sequence of the human corticotrophin releasing factor
precursor gene as published (Shibahara et al 1983). A primary
requirement of an oligonucleotide probe is that it must hybridise
specifically to the target gene sequence and not to unrelated sequences.
To this end, three sequences were chosen by Dr P Saunders (MRC
Reproductive Biology Unit) using the Genejockey programme written
by Dr Phil Taylor, (MRC Reproductive Biology Unit), featuring well
conserved regions of the molecule. After synthesis overnight, the
oligonucleotide probes were deprotected with ammonia (see Appendix
6). Oligonucleotide concentration was calculated by measuring the O.D
260 of 10pl of oligonucleotide solution in 1ml of water. The probes
were then 3' end-labelled with Digoxigenin-dUTP using terminal
transferase, the aim being to add 3-4 bases of digoxigenin-dUTP. The
efficiency of the labelling reaction was checked using 16%
polyacrylamide gel electrophoresis (PAGE). (For details of the labelling
reaction and the PAGE see Appendix 3).
The efficacy of these probes for in situ hybridisation was compared
with oligonucleotides of the same sequence commercially labelled with
digoxigenin dUTP (British Biotechnology products Ltd Abingdon Oxon
OX14 3YS UK).
4.2.3.2. Oligonucleotide probes specific for human CRH mRNA labelled
with 35s.
The oligonucleotides used were those used for digoxigenin labelling.
The protocol used was a 3' end-labelling reaction with 35gd ATP
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(W. Scott Young III In situ hybridisation with oligodeoxyribonucleotide
probes in In Situ Hybridisation, A Practical Guide Bios Scientific
publications) using terminal transferase. Terminal transferase from two
different sources were compared (Boeringer Mannheim and Promega).
For details of the method see Appendix 3.
4.2.3.3. POMC Riboprobe labelled with 35g
The POMC riboprobe was kindly donated by Dr Pamella Kolb,
department of Obstetrics and Gynaecology University of Washington
Seattle. The POMC insert was contained within a plasmid (pSP64 and
pSP65) with transcription initiation sites for the RNA polymerases SP6
and T7. These sites enabled transcription to be initiated in vitro in the
presence of labelled and unlabelled nucleotides resulting in the
formation of sense and antisense single stranded RNA riboprobes.
The labelled nucleotide used was 35g rCTP (Lot no. 89413 Amersham)
and the SP6 and T7 polymerase were obtained from Boehringer
Mannheim (lot no. 126/8820-03). The detailed reaction method is in
Appendix 3.
4.2.4. Composition of Hybridisation buffer
The degree of specificity of hybridisation reactions can be controlled
accurately by varying the reaction conditions. The temperature at which
hybridisation occurs depends on not only the probe construction, but
the concentration of salt and formamide in the hybridisation buffer.
4.2.4.1. Oligonucleotide probe hybridisation buffer.
The same hybridisation buffer was used for both digoxigenin-labelled
and 35s-labelled probes. Because the two antisense probes had different
GC nucleotide contents they required different buffer compositions to
enable their hybridisations to be performed at the same temperature.
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125(ig/ml salmon sperm DNA
125|ig/ml Yeast tRNA
43% formamide




125jig/ml salmon sperm DNA
125|ig/ml Yeast tRNA
37% formamide
4.2.4.2. Riboprobe hybridisation buffer
See appendix 3
Prehybridisation buffer was prepared as for hybridisation buffer except
the dextran sulphate was replaced by Stillplus water to reduce the
viscosity of the solution and facilitate its removal from the slides after
the prehybridisation stage. The sections were incubated in lOOpl of
prehybridisation buffer for 2.5 hours at a range of temperatures.
The hybridisation was performed in hybridisation buffer at a range of
temperatures. Each section was covered by 50(il of hybridisation buffer
containing probe at a concentration of lx 10^ counts for radioactively
labelled probes, or 1600, 800 or 400 pg/ml for digoxigenin-labelled probe.
The hybridisation time used in all cases was 18 hours.




4.2.5.1. Digoxigenin -labelled oligonucleotides
Different washing steps were compared to assess the effect on
background levels. The slides were first placed in 2xSSC to remove the
cover slips, and then washed in O.lx SSC for 15 minutes, four times at
a range of temperatures between 30 and 40°C.
4.2.5.2. 35S-labelled oligonucleotides
Again, different washing steps were compared to assess the effect on
background noise. The cover slips were removed in 2x SSC and the
slides washed four times in O.lxSSC for 15 minutes each, again at a
range of temperatures. The slides were then rinsed in a range of
washes of differing stringencies in order to improve signal/noise ratio.
4.2.5.3. 35s-labelled POMC Riboprobes.
Three protocols were tried;
4.2.5.3.1 12x15 minute washes in 4XSSC
30 minute wash in RNAse 20pg/l at 37°C
30 minute wash in RNAse buffer at 37°C
30 minute wash in 2xSSC at room temperature
30 minute wash in 2xSSC at 45°C
30 minute wash in 0.5xSSC at room temperature
4.2.5.3.2 2x 15 minute washes in 4xSSC
30 minute wash in RNAse 20(ig/l at 37°C
30 minute wash in RNAse buffer at 37°C
30 minute wash in 2xSSC at room temperature
30 minute wash in O.lxSSC at room temperature
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4.2.5.3.3 2x15 minute washes in 4xSSC
30 minute wash in RNAse 20(ig/l at 37°C
30 minute wash in RNAse buffer at 37°C
30 minute wash in lxSSC at room temperature
30 minute wash in O.lxSSC at room temperature
4.2.6. Detection of the in situ hybrids
Following the washes the slides were treated differently according to the
type of reporter used;
4.2.6.1 Digoxigenin- labelled probes.
1. The slides were treated with a blocking solution of normal sheep
serum (NSS) and tris-buffered saline (TBS) (1:5) for 30 minutes in a
humid conainer.
2. Antidigoxigenin-alkaline phosphatase Fab fragments in NSS/TBS (1:5)
at a dilution of 1:300 was applied and the slides left at room
temperature for 2 hours.
3. The slides were washed in TBS twice for 15 minutes.
4. The slides were washed for 2 minutes in digoxigenin detection buffer
5. Chromagen (NBT; for details see appendix 2) was added and the slides
were left to incubate overnight in the dark in a humid box at room
temperature for the colour to form.
6. After a further wash in digoxigenin detection buffer the slides were
dehydrated in absolute alcohol, cleared in xylene and mounted in
Eukitt.
4.2.6.2. 35s-labelled probes.
With both oligonucleotide and riboprobes, the procedure was the same.
The slides were dehydrated by passing through an alcohol series of 50%
and 85% (for 20 seconds each) containing 300mM of ammonium acetate
each to stabilise the hybrids, and then a 20 second wash in absolute
ethanol. The slides were left to air dry before dipping in photographic
emulsion (for method, see appendix 4a). The slides were left in dark
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boxes to expose for 3-6 weeks. After being developed (for details see
appendix 4b) the slides were counterstained with haematoxylin.
4.3. Results and Discussion
4.3.1 Fixation of Tissue
Optimal fixation conditions should preserve the maximum amount of
cellular RNA without disrupting normal morphology and at the same
time allow access for the probe. In vivo, messenger RNA is steadily
synthesised and degraded enzymatically. Out of the body, mRNA is
rapidly degraded, and consequently tissue should be fixed as soon as
possible. To this end all tissues used were placed in paraformaldehyde
within 30 minutes of delivery. Paraformaldehyde has previously been
successfully used to fix tissue for in situ hybridization in several studies
(Brigati et al 1983; Hafen et al 1983; MacAllister and Rock 1985; Hofler
et al 1986). Although it is a cross-linking fixative, it does not cross-link
proteins so extensively as to prevent tissue penetration by probes. Other
fixatives may preserve more RNA than paraformaldehyde but may
impair the accessibility of probes. Glutaraldehyde, has been reported to
preserve 20% more RNA but reduces accessibility to 40% (Singer et al
1987). It was decided to use 4% paraformaldehyde as a fixative because it
preserved morphology and antigenicity for immunocytochemistry
particularly when the tissue was fixed for the optimum twenty-two
hours, and yet would still allow probe penetration for in situ
hybridisation.
Tissue sections must adhere well to the glass slides during the rigorous
hybridisation procedure. To this end, the slides were first coated with
TESPA (See Appendix 1) (Burns et al 1987) which facilitates tissue
adherence.
Pretreatment of sections with proteinase digestion is a standard
procedure in almost all in situ hybridisation protocols, particularly
where cross-linking fixatives have been used. The combination of
proteinase K digestion with 0.2M HC1 wash increases the permeability
of tissue to probe, the protease by digesting the protein surrounding the
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nucleic acid sequence, and the HC1 by partial hydrolysis of the target
sequences. The acetylation step is used to reduce non- specific
electrostatic binding of the probe by neutralising positively charged
molecules and prevents non-specific binding of the probe to the slide.
Prehybridisation blocks non-specific protein and nucleic acid interaction
with the probe.
4.3.2. Probes
4.3.2.1. Oligonucleotide probes for CRH mRNA.
Synthetic oligonucleotides are conveniently prepared by DNA
synthesisers. The length of synthetic oligonucleotides (in this case
24-mer) is far shorter than riboprobes which may be 0.5-5 kb. This has
important consequences for hybrid stability and probe specificity. Their
main disadvantage is low specific activity when compared to riboprobes.
Shorter probes have an increased probability of finding a perfect match,
by chance alone. However, in situ hybridisation rarely discrimminates
between perfect and near perfect matches resulting in a lack of
specificity. This fact coupled with relatively low expression of CRH
mRNA, particularly in early placental tissue may explain the difficulties
encountered with the in situ hybridisation for CRH. The problems
encountered were twofold. Firstly, labelling of the oligonucleotide with
both radioactive and digoxigenin reporters was inconsistent and
therefore irreproducible (see section 4.3.3.). Secondly, when hybridisation
was attempted with labelled probe, there was considerable non-specific
binding of probe to all areas of the section, and there was no
significant difference between sense and antisense probes. It was
difficult to explain the inconsistency of the labelling since the
conditions were the same each time. The non-specificity of the probes
may have been secondary to the labelling difficulties, but may also be a
function of the low specificity of oligonucleotide probes. A specific
riboprobe for hCRHmRNA, such as that used for POMC may give
better results. Alternatively, a mixture of oligonucleotide probes can be
used to improve hybridisation specificity.
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4.3.2.2. POMC riboprobe
The POMC riboprobe is a single stranded RNA probe and was
synthesised and labelled simultaneously by in vitro transcription.
This reaction involves synthesis of the RNA strand by RNA polymerase
from radioactive and non-radioactive nucleotides. The polymerase used
depends on the RNA polymerase promoter found on either side of the
cloning site. The high specificity of each polymerase for its promoter
enables ssRNA probes to be generated complementary to the coding
(sense) or non-coding (antisense) strands. These probes have a higher
specific activity than DNA probes and also greater hybrid stability.
These factors favour increased sensitivity and consistency of reactions.
Furthermore, the use of RNAse in the post hybridisation wash will
result in digestion of unhybridised probe and so a reduction in
non-specific background noise. So, despite its increased length (sense
was 927 basepairs, antisense was 930 basepairs) when compared with the
oligonucleotide probe (24 basepairs), these factors probably explain its
increased specificity.
4.3.3. Probe labelling
Probe labelling may be either direct, with direct attachment of the
'reporter' molecule to DNA or RNA, or indirect, where a hapten e.g
digoxigenin is attached to the probe and detected by a labelled binding
protein or the probe-target hybrid is detected by a specific antibody.
Radioactively labelled probes are widely used, for several reasons; the
efficiency of probe labelling can be easily monitored, radioisotopes are
readily incorporated into the synthesised DNA and RNA, and
autoradiography with liquid emulsions is a fairly sensitive detection
system. 35g was chosen to label both the CRH oligonucleotide probe
and the POMC riboprobe because it produces reasonable resolution with
fairly short exposure particularly with low levels of gene expression.
The terminal transferase tailing method used to label the CRH
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oligonucleotide probe with 355 gaVe inconsistent and therefore
unreliable degrees of incorporation of radioactivity even when the
same batch of enzyme was used. Poorly labelled oligonucleotide resulted
in low signal in the resulting in situ hybridisation even when an
attempt was made to improve hybridisation and post-hybridisation
conditions. It was therefore decided to label the CRH oligonucleotides
with the non-radioactive label, digoxigenin. The digoxigenin system was
developed in the 1990s (Kessler 1990) and has been modified since. The
method is based on a steroid naturally found only in the foxglove,
digitalis purpura, and therefore there is no binding of the anti-DIG
antibody in other biological materials. Digoxigenin is linked to uridine
nucleotides and incorporated by terminal transferase to the 3' end of
the oligonucleotide. Detection is mediated by high affinity anti-
digoxigenin antibodies conjugated to alkaline phosphatase. The benefits
of this method over radioactive labelling are of speed of development
as well as eliminating the problems of safety and disposal of radioactive
material. However, the low level of expression and the problems of
using a single oligonucleotide probe may account for the complete lack
of staining achieved with this method of probe labelling for in situ
hybridisation. Using different concentrations of probe made no
difference to the result. A commercially obtained oligonucleotide probe,
labelled with digoxigenin (British Biotechnologies Ltd) was also
unsuccessful.
4.3.3.1. POMC riboprobe labelling with 35g
The POMC riboprobe was labelled with [^S] dCTP using SP6
polymerase using in vitro transcription. The detailed labelling reaction
is discussed in section 4.3.2.2. and the method given in Appendix 3.
The specific activity of the probe was assessed directly by counting lpl
of probe on a scintillation counter. Labelling of the riboprobe was more
successful than that of the CRH oligonucleotide probe. The appropriate
probe concentration for in situ hybridisation is one which produces the
largest signal to noise ratio. A concentration of lxlO^cpm per slide was
used for the in situ hybridisation as this gave the optimal signal
without increasing the background. See Plate 4.1.
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4.3.4. Hybridisation
The optimum conditions for hybridisation were sought. This depends on
several factors including the composition of hybridisation buffer, the
probe concentration, hybridisation temperature as well as the
pretreatment of the tissue already discussed. Hybridisation depends on
the ability of DNA to anneal with complementary strands in an
environment just below their melting point (Tm). The maximum
hybridisation rate is, however, about 15-20°C below the Tm. The Tm
depends on the length of the probe, its content of the bases guanine
and cytosine as well as the concentration of formamide and salt in the
hybridisation buffer. Higher salt concentrations increase the stability of
the hybrids.
The folowing equation has been given for the dependence of Tm on
the length (1) and G/C content of the probe, and the molar salt
concentration (M)
Tm = 16.6 log M +0.41 (G/C) +81.5 - (820/1)
However, increasing the salt concentration above 0.4M NaCl has little
effect on hybridisation or stability and the above formula does not hold
(Meinkoth and Wahl 1984).
The addition of formamide to the hybridisation solution, reduces the
melting temperature by 0.7°C for every 1% formamide added. It reduces
the thermal stability of double stranded polynucleotides, so that
hybridisation can be performed at lower temperatures. By varying the
amount of formamide used, the optimum temperature can be achieved
for hybridisation, whilst retaining good tissue morphology.
In aqueous solutions dextran sulphate is strongly hydrated producing a
volume exclusion effect leading to an apparent increase in probe
concentration and consequently higher hybridisation rates.
For the POMC riboprobe, the hybridisation was carried out at 50°C and
50% formamide as these conditions favoured the stability of well-
matched hybrids.
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The CRH oligonucleotide probes were hybridised at room temperature
with 43% formamide for antisense 1 and 37% formamide for antisense 2
and sense as theoretically these should be the most favourable
conditions. However, because of problems with labelling, results for
these probes were poor.
4.3.5. Post- hybridisation washes
The aim of this is to help to reduce background noise by removing
poorly matched hybrids. Labelled probe can hybridise non-specifically to
sequences which are similar but not entirely homologous to the probe
sequence. Such hybrids are less stable than perfectly matched hybrids.
They may be removed by washing with more stringent washes. As high
salt concentrations increase the stability of the hybrid, lowering the
concentration (ie a more stringent wash) will favour better matched and
therefore more stable hybrids. Equally, increasing the temperature of the
wash increases the stringency.
For the POMC riboprobe, increasing the stringency of the washes and the
addition of an RNAse wash to remove unhybridised probe decreased
the background, and the optimum post-hybridisation conditions were
found to be those described in section 4.2.5.3.3. See plates 4.1. and 4.2.
4.4. Conclusion
The final protocol used for all in situ hybridisation for POMC mRNA
in this thesis is as follows:
(for details of all solutions see Appendix 2)
1. 5pm paraffin sections were cut and floated onto TESPA coated
slides and baked overnight at 56°C.
2. The sections were dewaxed in xylene for 10 minutes and then
rehydrated in graded ethanols (100%, 95%, 75%).
3. The sections were washed in 0.2M HC1 for 20 minutes at room
temperature.
4. The sections were washed twice in stillplus water at room
temperature for 5 minutes each.
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5. The sections were digested with 2p.g/ml proteinase K in proteinase
K buffer for 30 minutes at 37°C.
6. The sections were placed in 0.2% glycine for 10 minutes at 4°C to
stop proteinase K action.
7. The sections were rinsed in TEA for 5 minutes and then acetylated
for 10 minutes with acetic anhydride in TEA.
8. Prehybridisation. The sections were incubated at 50°C for 2.5 hours
with prehybridisation buffer.
9. Hybridisation. The hybridisation was performed at 50°C for 18
hours in hybridisation buffer containing 50% formamide and
labelled 35S-POMC cDNA probe at a concentration of 1x10^ cpm per
slide.
10. Washes. After hybridisation the slides were immersed in 4x SSC to
remove the coverslips and then washed in the following solutions:
2X 15 min washes in 4XSSC
IX 30 min wash in RNAse 20pg/L at 37°C
IX 30 min wash in RNAse buffer at 37°C
IX 30 min wash in 1XSSC at room temperature
IX 30 min wash in 0.5XSSC at 45°C
IX 30 min wash in 0.1X SSC at room temperature.
11. Following the washes, the slides were dehydrated by passing
through an alcohol series (50%, 85%) containing 300mM
ammonium acetate to stabilise the hybrids, and one change of 100%
alcohol. The slides were coated with emulsion and left for 3 weeks
to expose.
12. After exposure, the slides were developed, (see appendix 4b)
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Plate 4.1. Determination of optimal conditions for the identification of
POMC mRNA in human placenta (1)
4.1.A & B Dark (A) and light (B) field micrographs of in situ
hybridisation of POMC mRNA in term placenta. Poorly
labelled probe. Note general non-specific effect.
4.1.C & D Dark (C) and light (D) field micrographs of in situ
hybridisation of POMC mRNA in term placenta. Probe used
at a concentration of 0.5 xlO6 counts per slide.
4.1.E & F Dark (E) and light (F) field micrographs of in situ
hybridisation of POMC mRNA in term placenta. Probe used
at a concentration of lxlO6 counts per slide and washed
using protocol 4.2.5.3.1.
The bar indicates 50pm
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Plate 4.2. Determination of optimal conditions for the
identification of POMC mRNA in human placenta (2)
4.2.A & B. Dark (A) and light (B) field micrographs of in situ
hybridisation of POMC mRNA in term placenta.
The washing conditions used were those detailed in section
4.2.5.3.2. Probe used at lxlO6 per slide.
4.2.C & D. Positive control. Dark (C) and light (D) field micrographs of
in situ hybridisation of POMC mRNA in piuitary. Probe used
at lxlO6 per slide.
4.2.E & F Dark (E) and light (F) field micrographs of in situ
hybridisation of POMC mRNA in term placenta. The
washing conditions used were those detailed in section
4.2.5.3.3. Probe used at lxlO6 per slide.
The bar indicates 50(im
80
CHAPTER 5
THE ONTOGENY OF CRH IN PLACENTA AND FETAL MEMBRANES
5.1. Introduction
As described in chapter 1, Corticotrophin-releasing hormone (CRH) is a
41 aminoacid hypothalamic peptide (Vale et al 1981), present in the
placenta from the first trimester onwards (Shibasaki et al 1982).
Placental peptide content (Sasaki et al 1987), CRHmRNA levels (Frim
et al 1988) and maternal plasma concentrations (Sasaki et al 1984;
Goland et al 1986; Campbell et al 1987; Laatikainen et al 1987b; Okamoto
et al 1989) all rise throughout gestation and fall rapidly after delivery.
These observations suggest that the placenta both synthesises and
releases increasing amounts of CRH throughout pregnancy.
Localisation of CRH in the placenta has been examined using
immunohistochemical techniques, but earlier reports are in conflict
with more recent observations. Two studies suggested that CRH
immunoreactivity was located in placental cytotrophoblast cells
(Petraglia et al 1987b; Saijonmaa et al 1988). However this cell type
decreases in number reaching relatively small numbers at term
(Gosseye and Fox 1984) when the concentration of CRH is at its
highest in the placenta, maternal plasma, and amniotic fluid (Maser-
Gluth et al 1987; Laatikainen et al 1988). More recently, Riley et al
(1991) have demonstrated CRH immunoactivity in the
syncytiotrophoblast cells of the placenta and also in the amnion,
chorion and decidua. These results are consistent with the large
numbers of syncytiotrophoblasts present at term. In addition, CRH is
released when cells from these tissues are cultured in vitro (Jones et al
1989; Jones and Challis 1989 Jones and Challis 1990a).
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The object of this part of the study was to examine the ontogeny of
CRH in the placenta and fetal membranes during pregnancy. This was
achieved by measuring the CRH content of placental and fetal
membrane extracts prepared from tissues collected at all gestational
ages. Specific cellular localisation within the same tissues was
accomplished by immunocytochemistry. An attempt was made to
determine the exact location of the expressed CRH gene using in situ
hybridisation.
5.2. Materials and methods
5.2.1. Tissue collection
Tissues were collected as described in Chapter 2. Briefly, all gestations
were calculated from the date of the last menstrual period and
confirmed by ultrasound and/or clinical assessment. Decidual and
trophoblastic tissues were obtained from patients undergoing therapeutic
termination of pregnancy in the first trimester for social reasons by
curettage, with (n=5) and without (n=5) pretreatment with the synthetic
prostaglandin analogue gemeprost (16,16, dimethyl transA^ PGEl
methylester) between 2 and 4 hours prior to the procedure and also
from patients undergoing therapeutic termination in the first
trimester(n=5) and second trimester induced by mifepristone and
prostaglandin (600mg of mifepristone orally 48hours prior to receiving
a lmg gemeprost vaginal pessary) (n=5). Placenta and fetal membranes
were also collected from spontaneous vaginal deliveries at term (n=7).
There was no clinical evidence of infection in any patient nor was
there any histological evidence (no inflammatory infiltrate) in any of
the tissues studied.
5.2.2. Tissue fixation
All tissues were divided into blocks of approximately 1.5 cm.3 and
placed in 4% (w/v) buffered paraformaldehyde (pH 7.4) within 30
minutes of delivery. Tissues were fixed at room temperature for 22
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hours, as this had been found to be the time required for good tissue
preservation and optimal staining (see chapter 2), processed in a
standard tissue processor and embedded in paraffin wax. Additional
tissue blocks were frozen in liquid nitrogen for later extraction and
measurement of CRH content.
5.2.3. Immunocytochemistry
Immunocytochemistry was carried out on 5pm sections of all tissues as
described in detail in chapter 3. A polyclonal CRH antisera raised in
rabbits against an ovine CRH-thyroglobulin-conjugate was used at an
optimum dilution of 1:1000. The following negative controls were used;
CRH primary antibody was substituted by antibody dilution buffer, non-
immunised rabbit serum (1:1000 dilution) or CRH antibody (1:1000)
dilution that had been preabsorbed with 5|iM human CRH (Bachem
UK Ltd Saffron Walden Essex WG 750) for 18 hours at 4°C. The
positive control used in each case was human term placenta.
5.2.4. Peptide Extraction
This was performed on all frozen tissue specimens as described in
chapter 2. Samples of placental extract were saved for protein
estimation (prior to centrifugation). 3ml aliquots were lyophilized, and
stored for radioimmunoassay and chromatography.
5.2.5. Radioimmunoassay
Each of the 3 ml lyophilized samples was reconstituted in 500pl of
CRH assay buffer. The concentration of CRH in each sample was
measured using a radioimmunoassay kit for human CRH (Penninsula
Laboratories, Westside Industrial Estate St Helens Merseyside England).
For details see chapter 2.
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5.2.6. Protein Estimation
Total protein content of the placental extracts was estimated using a
Biorad Protein assay (see chapter 2). CRH content of the extracts was
expressed in terms of total protein.
5.2.7. Sephadex Chromatography
To provide further evidence that the peptide in the placental extract
detected by radioimmunoassay was in fact CRH, placental extracts and
standard CRH, both reconstituted in CRH radioimmunoassay buffer,
were applied to a 50xlcm Sephadex G-50 Fine column (Pharmacia Fine
Chemicals Uppsala Sweden) equilibrated with CRH assay buffer. Sixty
lml fractions were collected at a constant flow rate of approximately
4ml/hour. Blue dextran was used to determine the void volume of
the column. All the fractions from the column were collected and
stored at -20°C for radioimmunoassay.
5.2.8. Data analysis
Tissue concentrations of CRH were compared by one-way analysis of
variance and Duncan's multiple range test with significance set at
p<0.05 (CLR ANOVA programme)
5.3. Results
5.3.1. Immunocytochemistry
Positive immunostaining for CRH was found in all placentas between
five and 42 weeks gestation regardless of method of termination of
pregnancy or delivery (Plate 5.1). There was a wide tissue-tissue
variation in the intensity of the staining which was not related to the
stage of gestation or method of termination or delivery, although the
distribution of the staining within the tissues was always the same. In
the control slides, no positive CRH immunoreactivity was found where
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primary antibody was substituted for antibody dilution buffer, non-
immunised rabbit serum or antibody that had been preabsorbed with
human CRH (see Plate 2.2F).
Between five and 12 weeks gestation positive CRH staining was found in
syncytiotrophoblast cells with faint staining in cytotrophoblast cells. Positive
staining was also seen in the cells of the decidual stroma. There was no
difference in staining in tissue obtained after suction curettage, with or
without prostaglandin pretreatment compared with tissue obtained after
termination with mifepristone and prostaglandins.
From the second trimester onwards (13-42 weeks gestation) positive CRH
staining was seen in syncytiotrophoblast but not cytotrophoblast cells. In
the amnion the staining was particularly pronounced in the epithelial
and subepithelial layers. The chorion stained in the trophoblast and
reticular layers. Cells of the decidual stroma also stained positively
throughout gestation, (see plate 5.1)
5.3.2. Radioimmunoassay
Radioimmunoassay of the placental extracts revealed a significant
(p<0.01) increase in CRH content with advancing gestation (Fig. 5.1).
Average CRH concentrations were 62.69 ± 6.62 pg/mg protein in first
trimester placenta (n=15); 237.5 + 38.31pg/mg protein in second trimester
placenta (n=5) and 741.47 + 70.47pg/mg protein in term placenta (n=17).
There was no significant difference in placental CRH concentration with
different modes of delivery (Fig. 6.2), or the administration of
prostaglandin E2 or the antiprogestin mifepristone (Fig. 6.1), and
therefore all the results from each trimester were grouped together
regardless of mode of delivery (Figure 5.1). There was a significantly
(p<0.01) greater concentration of CRH in placenta than in amnion
75.2±12.5 pg/mg protein (n=17), chorion 131.9+24 pg/mg protein (n=17)
or decidua 114.97+25 pg/mg protein (n=17). (Fig. 5.2)
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5.3.3. Chromatography
Standard CRH and CRH in placental extracts eluted with an identical
retention time suggesting that extracted placental CRH had the same
molecular weight as standard CRH (See Figure 5.3)
5.4. Discussion
This study clearly demonstrates that CRH immunoreactivity is present
in the placenta and its localisation is constant throughout pregnancy.
Positive CRH immunostaining was observed in the syncytiotrophoblast
and decidua as early as five weeks gestation and in the amnion and
chorion from 13 weeks gestation (the earliest available time these
membranes could reliably be collected), and these results are consistent
with the detection of CRH by radioimmunoassay in placental extracts at
this stage of gestation. The localization of CRH in placenta so early in
gestation is in contrast to a recent report in which CRH could not be
detected until the second trimester (Riley et al, 1991). However, CRH is
detectable in maternal plasma during the first trimester, albeit at low
levels, and CRH mRNA has been demonstrated in the placenta by
Northern analysis as early as seven weeks gestation (Frim et al, 1988). In
addition, in vitro studies of cultured placental and amnion cells at 12
weeks gestation have shown a significant output of CRH, data which
supports the finding of positive CRH immunostaining in the first
trimester (Jones & Challis, 1990a). In previous studies positive
immunostaining has been reported in cytotrophoblasts (Petraglia et al.,
1987a; Saijonmaa et al., 1988). Saijonmaa et al (1988) used a high
concentration of antibody with no preabsorbed control and found
immunostaining in the first trimester but not at term. These workers
attributed this to the relatively small numbers of cytotrophoblast cells at
term but did not account for the very high levels of CRH found in the
placenta at this time. Petraglia et al (1987a) found CRH immunopositive
staining in cytotrophoblasts at term but again this finding does not
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account for high levels of circulating CRH. These data demonstrating
CRH immunostaining in the large numbers of syncytiotrophoblasts at
term is consistent with the high maternal plasma and amniotic fluid
levels and agrees with the immunohistochemical findings of Riley et al
(1991). Furthermore, in vitro studies of cultured placental, amnion,
chorion and decidual cells at term have demonstated significant CRH
output at this time. The difference between these studies are difficult to
explain but may relate to different methods of tissue collection and
fixation, or to the antibodies used.
Immunostaining is not a reliable method for quantification as intensity
of staining does not necessarily reflect peptide content. In addition there
was much variability both within and between tissues of intensity of
staining, although the distribution of the staining was always the same.
In view of this, the CRH peptide content of the same groups of tissues
was measured. The results of this was entirely in agreement with
previous findings of peptide content (Sasaki et al 1987). It was hoped
that in situ hybridisation, in conjunction with immunocytochemistry,
would provide further evidence for the site of synthesis of CRH.
Unfortunately, problems with the specificity of the oligonucleotide
probes made for this purpose affected the reproducibility of the results
(see Chapter 4). More reliable results may be achievable by using a
riboprobe and would provide valuable information of both the site of
synthesis, and quantification of placental CRH.
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Figure 5.1
Change in the concentration of CRH measured by radioimmunoassay in
extracts of placenta collected at various stages of pregnancy. Each
histogram represents the mean ± SEM of 15, 5 and 17 measurements in
first, second and third trimester tissues, respectively. Values with











Immunoreactive CRH concentration measured by radioimmunoassay in
extracts of placenta, amnion, chorion and decidua collected after
spontaneous delivery at term (n=7) Values are the mean ± SEM. Values
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Figure 5.3. Immunoreactive CRH measured by radioimmunoassay in
fractions of placental extract applied to a sephadex G-50 fine column.
The bar indicates the fractions in which standard human CRH was
eluted from the same column; placental CRH extract and standard
human CRH eluted with an identical retention time. The void volume












Plate 5.1. CRH immunolocalisation in placenta and fetal membranes
throughout gestation
5.1.A. Placental villi obtained after suction termination of
pregnancy at 8 weeks gestation. CRH immunostaining is
seen in the syncytiotrophoblast.
5.I.B. Placental villi obtained after termination of pregnancy in the
second trimester. CRH immunostaining is seen in the
syncytiotrophoblast
5.l.C. Placental villi demonstrating positive CRH immunostaining
in syncytiotrophoblast from a normal vaginal delivery at
term.
5.I.D. Amnion from a normal term vaginal delivery
demonstrating CRH immunostaining in the epithelial and
subepithelial layers.
5.I.E. Chorion from a normal term vaginal delivery
demonstrating CRH immunostaining in the reticular and
cellular layers.
5.I.F. Decidua from a normal term vaginal delivery demonstrating
CRH immunostaining in the decidual stromal cells.




ONTOGENY OF ACTH IN PLACENTA AND FETAL MEMBRANES
6.1. Introduction
Adrenocorticotrophic Hormone (ACTH) is a 39 amino acid peptide,
which is synthesised as part of the proopiomelanocortin precursor
molecule. Since the early 1950' s it has been suggested that the
human placenta may influence the hypothalamopituitary adrenal axis
during pregnancy by synthesising and secreting a wide range of peptides
normally of hypothalamic or pituitary origin including ACTH (Jailer and
Knowlton 1950; Silman and Bergman 1953; Assali and Hammermetz 1954).
This placental ACTH could potentially stimulate the HPA axis in the
mother or the fetus by stimulating adrenal steroidogenesis. This may be
of particular significance in the fetus, since the fetal adrenal cortex
supplies the placenta with androgens for oestrogen synthesis throughout
pregnancy, and secretes Cortisol which is essential for late fetal
maturation.
Some studies have found the concentration of ACTH in maternal
plasma to rise during pregnancy (Rees et al 1975; Carr et al 1981) and
synthesis in vitro of both bioactive and immunoreactive ACTH by
human placenta at term and in the first trimester has been reported.
There is some disagreement as to whether placental ACTH levels rise
or stay constant during pregnancy. Immunoreactive POMC- derived
peptides have been detected in the human placenta and de novo
synthesis of POMC and its derived peptides has been demonstated in
cultures of human trophoblasts (Liotta et al 1977, Waddell et al 1993)
Furthermore, POMC mRNA has been detected in human placenta at
term (Cheng et al 1986). Immunoreactive ACTH has been localised
immunocytochemically to the syncytiotrophoblast (Al-Timini & Fox
1986) and showed a similar intensity of staining in first and third
trimester placentae, agreeing with those studies that indicated little or
no variation in the levels of placental ACTH secretion throughout
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pregnancy (Liotta et al, 1977, Odagiri et al 1979) In view of the potential
role of ACTH in controlling the HPA axis throughout pregnancy and
its possible role in the onset of parturition, this part of the study
examined the localisation and content of IR-ACTH in placenta and fetal
membranes throughout gestation and the expression of the POMC gene
in the same tissues. Thus both the mRNA transcribed from the gene
and the gene product translated from the mRNA could be identified.
Since there is some disagreement over the quantification of ACTH
during pregnancy, it was hoped that this information would provide
strong evidence for both the site of synthesis and the control of
expression of placental POMC peptides.
6.2. Materials and methods
For a detailed description of the development of these methods see
chapters two, three and four.
6.2.1. Tissue collection and fixation
Tissues were collected and fixed as described in chapter 5.
6.2.2. Immunocytochemistry
Immunocytochemistry was carried out on 5(im sections of all tissues as
described in detail in chapter 3. A polyclonal CLIP antisera raised in
rabbits against a human CLIP-thyroglobulin-conjugate was used at an
optimum dilution of 1:1000. This antibody shows 100% cross-reactivity
with ACTH (1-39). The following negative controls were used; CLIP
primary antibody was substituted by antibody dilution buffer, non-
immunised rabbit serum (1:1000 dilution) or CLIP antibody (1:1000)
dilution that had been preabsorbed with 5jiM human ACTH (Cambridge
Research Biochemicals lot Z1975) for 18 hours at 4°C. The positive
control used in each case was adult sheep pituitary.
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6.2.3. Peptide extraction and radioimmunoassay
Peptide was extracted from frozen blocks of tissue as described in
chapter 4. An aliquot of each sample (prior to centrifugation) was
stored at 4°C for later protein estimation. A further two 3ml aliquots
were lyophilised and stored for radioimmunoassay and chromatography.
Each of the 3 ml lyophilised samples were brought up to 500jil in
ACTH assay buffer. The concentration of ACTH in each sample was
measured using a direct radioimmuoassay as described in chapter 2.
Total protein content of the placental extracts was estimated using a
Biorad protein assay (see chapter 2). ACTH content of the extracts was
expressed in terms of total protein.
6.2.4. Sephadex chromatography
Placental extracts and standard human ACTH were applied to a 50x1 cm
glass chromatographic column containing sephadex G-50 Fine (Pharmacia
Fine Chemicals Uppsala Sweden) equilibrated with ACTH assay buffer.
2mls of 10% bovine serum albumin solution were added to reduce
non-specific binding. Sixty 1ml fractions were collected at a flow rate of
approximately 4 ml/hr. Blue dextran was used to determine the void
volume of the column. All the fractions from the column were
collected and stored at -20°C for radioimmunoassay
6.2.5. Data analysis
Tissue concentrations of ACTH were compared by one-way analysis of
variance and Duncan's multiple range test with significance set at
p<0.05 (CLR ANOVA programme)
6.2.6. In situ hybridisation
In situ hybridisation was performed on 5|im paraffin embedded sections
using the protocol developed as described in chapter 3. Sections of adult
sheep pituitary were used as a positive control and a sense probe
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complementary to antisense used as a negative control. All slides were
counterstained with haematoxylin and eosin, dehydrated and mounted
in Eukitt. In situ hybridisation signals from each study group were
quantified using a computer-assisted image analysis system. Six areas of
trophoblast, and six areas of tissue background from each slide were
randomly chosen and the number of grains/cm^ counted. The system
consisted of a Charge-Coupled Device camera, microscope, and camera
monitor linked to a IBM PC/AT microcomputer. The software program
(cue-2) for densitometry was provided by Olympus Optical Company. An
optimum threshold and filter combination were set to select only the
silver grains. The grain count from the six areas was calculated as a
mean and the mean background subtracted. The mean grain count
between sense and antisense were compared, and the sense counts
always approximated to antisense background values.
6.3. Results
6.3.1. Immunostaining
Positive immunostaining for ACTH was found in all placentas between
5 and 42 weeks gestation regardless of the method of termination of
pregnancy or delivery (see plate 6.1). In control slides, no positive
ACTH immunostaining was found where the primary antibody had
been substituted by antibody dilution bufer or non-immunised rabbit
serum or CLIP antibody at 1:1000 dilution which had been preabsorbed
overnight with 5jiM ACTH (see plate 2.3.).
In the first trimester (from 5-12 weeks gestation) positive staining was
seen in the cytotrophoblast layer of cells, with none in the
syncytiotrophoblast. Positive staining was also seen in the cells of the
decidual stroma. The staining was faint when compared with tissue of
more advanced gestation. From the second trimester onwards, positive
ACTH immunostaining was seen in the syncytiotrophoblast.
The staining increased in intensity with advancing gestation. In the
amnion the staining was particularly pronounced in the epithelial layers
with also some staining in the subepithelial layer. In the chorion
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staining was seen mainly in the reticular layer. Cells of the decidual
stroma stained positively throughout gestation, (see plate 6.1)
6.3.2. Radioimmunoassay
Radioimmunoassay of the placental extracts revealed a significant
(p<0.01) increase in ACTH content in the third trimester, agreeing with
the observation that the intensity of the staining appeared to increase
(see figure 6.1). Mean ACTH in term placenta (n=17) was
29.39±4.59pg/mg protein, in second trimester placenta (n=5) was
10.22±1.81pg/mg protein and in first trimester placenta (n=15) was
7.35±0.83pg/mg protein. There was no significant difference in placental
ACTH content with different modes of delivery (Fig 8.2), or the
administration of prostaglandin E2 or the antiprogestin mifepristone (Fig
8.1), so all term and all first trimester data were considered together.
There was a significantly (p<0.01) greater concentration of ACTH in
placenta than in amnion 13.5+1.9 pg/mg protein (n=17), chorion 16.6±2.3
pg/mg protein (n=17) or decidua 11.39±1.34 pg/mg protein (n=17) (Fig.
6.2).
6.3.3. Chromatography
Sephadex G50 chromatography revealed that ACTH from placental
extracts and human ACTH (1-39) standard eluted with an identical
retention time, indicating that they have the same molecular weight
(see Fig 6.4).
6.3.4. In situ hybridisation
In common with the immunocytochemical results, in situ hybridisation
localised POMC mRNA to the trophoblast cells at all stages of
pregnancy. It was less easy to distinguish between cytotrophoblast and
syncytiotrophoblast cells in the first trimester and it appeared that grains
were present in both types of cell. In the second and third trimester,
mRNA was present in the syncytiotrophoblasts (see plate 6.2). Image
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analysis of grain density revealed that the intensity increased
significantly between the first trimester(0.76±0.07grains/cm2xl05) and the
third(2.97±0.2grains/cm2xl05) (Fig 6.3) suggesting an increase in POMC
gene expression over this time. In situ hybridisation also localised
POMC mRNA particularly to the epithelial layers of the amnion with
also some expression in the subepithelial layer. In the chorion POMC
gene expression was seen mainly in the reticular layer (see plate 6.3)
6.4. Discussion
These results demonstrate positive ACTH immunostaining and POMC
gene expression in the placenta throughout pregnancy. ACTH
immunostaining is seen in the cytotrophoblasts and decidual stroma as
early as five weeks gestation and in the fetal membranes from the
second trimester onwards (the earliest time these tissues could be
reliably collected). Extraction of peptide from the placenta and
radioimmunassay for ACTH revealed detectable levels at all stages of
pregnancy. The concentrations of ACTH measured in placental extracts
were similar to those reported previously by Liotta et al (1977), Rees et
al (1975) and Odagiri et al (1989).
The intensity of the immunostaining increased throughout gestation
but its localisation changed from the cytotrophoblast in the first
trimester to the syncytiotrophoblast thereafter. The intensity of the in
situ hybridisation signal increased in parallel but appeared to be present
in both cytotrophoblast and syncytiotrophoblast in the first trimester.
The placental ACTH content was also significantly greater at term than
in the first trimester. Previous ACTH immunostaining (Al-Timini and
Fox 1986) localised ACTH to the syncytiotrophoblast throughout
gestation and found no change in the intensity or the localisation of the
immunostaining, although they noted that it always occured at a low
level. They used an anti-ACTH antiserum at very low dilution of 1:100
compared with the 1:1000 dilution of anti-CLIP antiserum used in this
study. The use of antiserum to a smaller antigen (CLIP versus ACTH)
may have affected tissue penetration of the antigen or altered the
antigen-antibody binding, although the specificity of this binding was
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unaltered as demonstrated by the loss of positive staining when
antiserum preabsorbed with human ACTH was used. Use of a higher
dilution of antibody reduces background staining, an advantage of using
1:1000 dilution of anti-CLIP antibody. Studies of placental ACTH content
which do not show any variation in placental ACTH content
throughout pregnancy (Liotta et al 1977; Rees et al 1975; Odagiri et al
1979 ) support the findings of Al-Timini and Fox. However, the findings
of this study, demonstrating an increase in placental ACTH content
with gestation, and the increase in POMC gene expression, strongly
support the staining results seen using anti-CLIP antiserum. The
demonstration of positive immunostaining of cytotrophoblast cells in
the first trimester, and syncytiotrophoblasts thereafter is consistent with
the changing numbers of these cells during pregnancy. Cytotrophoblasts
are more numerous in the first trimester but in later pregnancy
syncytiotrophoblasts (the mitotic end stage of cytotrophoblasts)
predominate. This is consistent with the rising concentration of ACTH
detected in the placenta in later pregnancy in this study. In addition, a
progressive rise in plasma ACTH has been demonstrated during
pregnancy (Rees et al 1975; Carr et al 1981) although most values lay
within the normal range. If the placenta is the source of at least a
proportion of this maternal plasma ACTH, then the change in plasma
concentration may reflect increasing placental synthesis of ACTH.
The POMC gene appears to be expressed in both cytotrophoblasts and
syncytiotrophoblasts in the first trimester, although the peptide is only
detectable by immunocytochemistry in the cytotrophoblasts at this time.
Perhaps the gene is transcribed from both types of cell but translation
only occurs in the cytotrophoblasts. The syncytiotrophoblasts appear to
be derived from cytotrophoblasts. At this early stage, these recently
transformed cells may not have the full synthetic capability for the
production of POMC derived peptides. This may be linked to their
function. If their role is in the initiation of parturition, then high
output would be unnecessary early in pregnancy.
However, the biological significance of this placental ACTH remains
uncertain. Potentially placental ACTH could stimulate adrenal
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steroidogenesis in the mother or the fetus and thus influence their
respective hypothalamo-pituitary-adrenal axes. In the rat and rhesus
monkey (Knobil and Briggs 1955; Hodgen et al 1975) pregnancy reduces
the extent of adrenal atrophy that ocurs in response to maternal
hypophysectomy. After removal of the fetus (but not the placenta)
Cortisol levels remained relatively high , but then fell dramatically after
placental delivery (Hodgen et al 1975) suggesting direct placental support
for the maternal adrenal cortex. Circumstantial evidence supports a role
for the placenta in maintaining fetal or maternal adrenal function
during human pregnancy. Growth of the fetal adrenal cortex appears to
be normal in anencephalic fetuses up to mid-gestation (Benirschke 1956)
and since ACTH does not cross the placenta (Dupouy et al 1980) this
suggests that some factor other than fetal pituitary ACTH is trophic to
the fetal adrenal. It is likely that at least some of this support could
come from the placenta. The demonstration of ACTH immunoreactivity
from early to late gestation suggests that the placenta may exert this
effect throughout the whole of pregnancy. Its role in relation to labour
is more speculative. It has been hypothesised that activation of the fetal
hypothalamo-pituitary-adrenal axis may be linked with the onset of
parturition, with placental CRH passing into the fetal circulation causing
the release of ACTH from the fetal pituitary and an increase in plasma
Cortisol. This ACTH also increases DHEAS resulting in increased
oestrogen output by the placenta. The Cortisol may also stimulate
placental CRH production in a positive feedback loop. The effects of
placental CRH on prostaglandin production and myometrial contractility,
as discussed in Chapter 1, could lead to ripening of the cervix and
myometrial contractility (Challis and Hooper 1989) and ultimately birth.
Placental ACTH may too pass into the fetal circulation and affect
Cortisol production by the fetal adrenal. The finding of a rise in
placental ACTH content in the third trimester prior to labour supports
the hypothesis that placental ACTH may also be involved in the
activation of the fetal hypothalamo-pituitary-adrenal axis. In view of
this, further studies were undertaken to investigate the modulation of
placental ACTH by labour, the administration of prostaglandins and the
administration of the antiprogestin mifepristone (see Chapter 8)
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Figure 6.1.
Change in the concentration of ACTH measured by radioimmunoassay
in extracts of placenta collected at various stages of pregnancy. Each
histogram represents the mean ± SEM of 15, 5 and 17 measurements in
first, second and third trimester tissues, respectively. Values with































Immunoreactive ACTH concentration measured by radioimmunoassay in
extracts of placenta, amnion, chorion and decidua collected after
spontaneous delivery at term (n=7) Values are the mean ± SEM. Values









Change in POMC gene expression measured by quantification of in situ
hybridisation performed on sections of placentas collected at various
stages of pregnancy. Each histogram represents the means of six random
counts of the tissue grain density (background non-specific counts have
been subtracted) of each of three tissues from the first and third















Figure 6.4. Immunoreactive ACTH measured by radioimmunoassay in
fractions of placental extract applied to a sephadex G-50 fine column.
The bar indicates the fractions in which standard human ACTH was
eluted from the same column; placental CRH extract and standard
human ACTH eluted with an identical retention time. The void
volume of the column (Vo) is indicated.
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Plate 6.1. ACTH immunolocalisation in placenta and fetal
membranes throughout gestation
6.1.A. Placental villi obtained after suction termination of
pregnancy at 8 weeks gestation. ACTH immunostaining is
seen in the cytotrophoblast.
6.I.B. Placental villi obtained after termination of pregnancy in
the second trimester. ACTH immunostaining is seen in the
syncytiotrophoblast
6.l.C. Placental villi demonstrating positive ACTH
immunostaining in syncytiotrophoblast from a normal
vaginal delivery at term. Note the increased intensity of the
staining.
6.I.D. Amnion from a normal term vaginal delivery
demonstrating ACTH immunostaining in the epithelial and
subepithelial layers.
6.I.E. Chorion from a normal term vaginal delivery
demonstrating ACTH immunostaining in the reticular and
cellular layers.
6.I.F. Decidua from a normal term vaginal delivery demonstrating
ACTH immunostaining in the decidual stromal cells.
The bar indicates 50pm
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Plate 6.2. In situ hybridisation of POMCmRNA within placenta
throughout gestation
6.2.A & B Dark (A) and light (B) field micrographs of in situ
hybridisation of POMC mRNA in first trimester
placenta. Note the grains over the trophoblast cells.
6.2.C Negative control. Tissue shown in 6.2.A but using
sense probe. Note low level of non specific
hybridisation.
6.2.D & E Dark (D) and light (E) field micrographs of in situ
hybridisation of POMC mRNA in second trimester
placenta. Note the grains over the trophoblast cells.
6.2.F Negative control. Tissue shown in 6.2.D but using
sense probe. Note low level of non Specific
hybridisation.
6.2.G & H Dark (G) and light (H) field micrographs of in situ
hybridisation of POMC mRNA in term placenta. Note
the increased density of grains over the trophoblast
cells.
6.2.1 Negative control. Tissue shown in 6.2.G but using
sense probe. Note low level of non specific
hybridisation.
The bar indicates 50gm
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Plate 6.3. In situ hybridisation of POMC in the fetal membranes
6.3.A &B Dark (A) and light (B) field micrographs of in situ
hybridisation of POMC mRNA in amnion collected at
term.
6.3.C Negative control. Tissue shown in 6.3.A but using
sense probe. Note low level of non specific
hybridisation.
6.3.D & E Dark (D) and light (E) field micrographs of in situ
hybridisation of POMC mRNA in chorion collected at
term.
6.3.F Negative control. Tissue shown in 6.3.D but using
sense probe. Note low level of non specific
hybridisation.
The bar indicates 50(im
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CHAPTER 7
MODULATION OF PLACENTAL CRH PRODUCTION
7.1. Introduction
As discussed in Chapter 5, CRH is present in the placenta and fetal
membranes from the first trimester onwards. The results of placental
and membrane CRH content seen in chapter 5 are consistent with
earlier findings that placental peptide content (Sasaki et al 1987),
CRHmRNA levels (Frim et al 1988) and maternal plasma concentrations
(Sasaki et al 1984; Goland et al 1986; Campbell et al 1987; Laatikainen
et al 1987b; Okamoto et al 1989) all rise through gestation and fall
rapidly after delivery. These observations suggest that the placenta both
synthesises and releases increasing amounts of CRH throughout
gestation. In addition maternal plasma CRH levels rise prior to
delivery, and in women who subsequently go into preterm labour,
abnormally high levels of CRH are seen several weeks before delivery
(Campbell et al 1987), suggesting its possible invovement in the
initiation of parturition. Furthermore, plasma levels of CRH are elevated
during labour peaking at delivery, suggesting a possible role in the
progress of labour (Schulte et al 1987).
In sheep, parturition is preceeded by a rise in the levels of myometrial
stimulants oestrogens and prostaglandins combined with a fall in the
level of the myometrial relaxant progesterone (Csapo et al 1961). There
is no such change in plasma progesterone concentations in women at
the time of labour. Paradoxically, antiprogestins are effective
abortifacients in both animals and humans and have been shown to
increase myometrial sensitivity to prostaglandins (Rodger & Baird, 1987;
Rodger et al., 1988; Garfield & Baulieu, 1987). In vitro cell culture
experiments using human amnion and placental tissue, have shown
that progesterone decreases CRH output from amnion cells in early
pregnancy (Jones & Challis, 1990a) and from both tissue types at term
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(Jones et al., 1989). It has been suggested that progesterone has an
inhibitory effect on placental CRH production during pregnancy until
term when a local change, possibly at the receptor level, may remove
this inhibition (Challis & Olson, 1988). Furthermore, CRH stimulates
prostaglandin production (Jones & Challis, 1990b). Thus, rising CRH
concentrations as a result of local progesterone withdrawal would cause
an increase in prostaglandin production and lead to cervical ripening
and myometrial contractility. In addition, CRH may act directly on the
myometrium which contains specific binding sites for CRH. These
increase in affinity for CRH during pregnancy which may influence
parturition by sensitising the myometrium to uterine agonists (Hillhouse
et al., 1993).
In view of the potential role of CRH in the control of parturition, the
localisation of CRH in the placenta and fetal membranes from the first
trimester onwards, and the CRH content of the same tissues, was
examined. By comparing tissues collected after elective caesarean
section, spontaneous and induced labours, the effect of labour and of
the administration of exogenous prostaglandins, on both CRH
immunolocalisation and on tissue content could be compared. In the
first trimester, the antiprogestin mifepristone was used to determine
whether progesterone has a regulatory effect on CRH production and
the effect of exogenous prostaglandins was also studied.
7.2. Materials and Methods.
7.2.1. Tissue collection
All gestations were calculated from the date of the last menstrual
period and were confirmed by ultrasound assessment and/or clinical
assessment. Decidual and trophoblast tissues were obtained from
patients undergoing therapeutic termination of pregnancy in the first
trimester by curettage with (n=5) and without (n=5) pretreatment with
the synthetic prostaglandin analogue gemeprost (16,16, dimethyltrans
PGEi methylester) between 2 and 4 hours prior to the procedure and also
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from pateints undergoing therapeutic termination in the first (n=5) and
second (n=5) trimesters using mifepristone 600mg orally 48 hours prior
to receiving a lmg gemeprost vaginal pessary. All patients aborted
within 6 hours. Placenta and fetal membranes were also collected from
spontaneous vaginal deliveries at term (36-42 weeks gestation) (n=7), by
elective caesarean section (n=5), and by induction of labour using
prostaglandin E2 (n=5) (all patients studied recieved 2mg of PGE2 and all
delivered within 24 hours). There was no clinical or histological
evidence of infection in any patient.
The materials and methods used were identical to those used in
chapter 5. Briefly, tissues were collected, fixed in 4% paraformaldehyde
and examined immunocytochemically. Peptide content in placental
extracts was measured by radioimmunoassay and sephadex
chromatography was used to examine the molecular size forms of
placental CRH.
7.3. Results
Positive immunostaining for CRH was found in all placentas between
five and 42 weeks gestation regardless of method of termination of
pregnancy or delivery (see plate 5.1). There was some tissue-tissue
variation in the intensity of the staining which was not related to the
stage of gestation or method of termination or of delivery, although the
distribution of the staining within the tissues was always the same.
In the control slides, no positive CRH immunoreactivity was found
where primary antibody was substituted for antibody dilution buffer,
non-immunised rabbit serum or antibody that had been preabsorbed
with human CRH. (see plate 3.2)
Between five and 12 weeks gestation positive CRH staining was found in
syncytiotrophoblast cells with faint staining in cytotrophoblast cells.
Positive staining was also seen in the cells of the decidual stroma.
There was no difference in staining in tissue obtained after suction
curettage, with or without prostaglandin pretreatment compared with
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tissue obtained after termination with mifepristone and prostaglandins
(see plate 7.1).
From the second trimester onwards (13-42 weeks gestation) positive CRH
staining was seen in syncytiotrophoblast but not cytotrophoblast cells.
In the amnion the staining was particularly pronounced in the
epithelial and subepithelial layers. The chorion stained in the
trophoblast and reticular layers. Cells of the decidual stroma also
stained positively throughout gestation. There was no difference in
staining in tissue obtained from elective caesarean section (not in
labour) at term compared with that from spontaneous vaginal delivery
at term. There was also no difference in staining in tissue obtained
after labour induced with prostaglandins compared with that from
spontaneous labour (see plates 7.2 and 7.3).
Radioimmunoassay of the placental extracts revealed a significant
(p<0.01) increase in CRH content with advancing gestation (see chapter
5). There was no significant difference in placental CRH concentration
with the administration of prostaglandin E2 or the antiprogestin
mifepristone (Fig 7.1) in the first trimester, or with different modes of
delivery at term (Fig 7.2). Average CRH concentrations in first
trimester placental extract collected after curettage with (61.52±11.99pg/mg
protein) and without (61.36±8.51pg/mg protein) pretreatment with
prostaglandin, and (65.20±15.53pg/mg protein) in first trimester placental
extracts collected after termination with mifepristone. Placental CRH
concentrations in extracts collected after spontaneous, induced and
caesarean deliveries were 794.14±131.61pg/mg protein, 713.4±109.18pg/mg
protein, and 694.4±130.32pg/mg protein respectively. There was also no
significant difference in the content of CRH of the fetal membranes and
decidua with different modes of delivery at term (Fig 7.3). Thus, the
content of CRH in the fetal membranes was also not affected by labour,
prostaglandins or mifepristone.
Standard CRH and CRH in placental extracts eluted with an identical
retention time suggesting that extracted placental CRH had the same
molecular weight as standard CRH (See Figure 5.3)
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7.4. Discussion
This study clearly demonstrates that CRH immunoreactivity is present in the
placenta and its localisation is constant throughout pregnancy. There was no
difference in the intensity of the staining in tissues obtained after
elective caesarean section compared to those collected after spontaneous
or induced labour at term. This was consistent with the finding that
the CRH content of these tissues was not affected by labour. This is in
contrast to previous investigations of the effects of labour on placental
CRH content (Saijonmaa et al 1988). This study found CRH
immunostaining in first trimester placenta, but were unable to
immunolocalise CRH in term placentae. However, using the same
antibody in a radioimmunoassay, they found the mean concentration of
CRH in placental tissue to be significantly larger after spontaneous
vaginal delivery than after elective caesarean section.
The hypothesis that progesterone may have a regulatory effect on
placental CRH production was tested using the antiprogestogen,
mifepristone. There was no difference in intensity of staining in
placentas from patients pretreated with mifepristone compared to those
who were not, and in addition to this, there was no significant
difference in the CRH content of these placentas compared with those
obtained after suction termination. Forty-eight hours of exposure to
mifepristone is likely to be a sufficient duration to produce an increase
in peptide synthesis, however the anti-glucocorticoid side effects of
mifepristone may counteract its anti-progestogenic effects since
glucocorticoids have been shown to stimulate CRH release by the
placenta and fetal membranes in vitro (Jones et al., 1989; Jones & Challis,
1990a). Another explanation for the lack of effect of mifepristone on
CRH concentration may relate to the early stage of gestation when these
studies were conducted. In vitro studies have demonstrated that
progesterone inhibits CRH release by the placenta at term (Jones et al.,
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1987) but has no effect in early pregnancy (Jones & Challis, 1990a). It may
be that mifepristone given later in pregnancy would affect output of
CRH whereas in the first trimester it does not. The logical next step
would be to investigate the effect of mifepristone on placental CRH
content at term when used as an agent for the induction of labour.
Nonetheless, treatment with mifepristone results in a clinical effect
producing abortion. It would appear from the data that this effect of
mifepristone is not mediated via the induction of CRH synthesis as
CRH appeared to be constitutively present in all tissues studied.
This does not preclude more subtle changes in the synthesis or export
of CRH which might be important in the physiological or
pharmacological control of uterine contractility. In addition, the
constitutive presence of CRH in syncytiotrophoblast suggests that it may
play a "housekeeping" role in the placenta and membrane unit rather
than simply being related to parturition.
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Figure 7.1.
Immunoreactive CRH concentrations measured by radioimmunoassay in
first trimester placental extracts collected after termination of pregnancy
induced by mifepristone (RU486) (n=5), curettage with prostaglandin
(STOP+C) (n=5), or curettage without prostaglandin (STOP-C) (n=5).
































Immunoreactive CRH concentration measured by radioimmunoassay in
extracts of placenta collected after spontaneous (n=7), induced (n=5) or
caesarean delivery (n=5) at term. Values are the mean ± SEM.
































Immunoreactive CRH concentration measured by radioimmunoassay in
extracts of amnion, chorion and decidua collected after spontaneous
(n=7), induced (n=5) or caesarean delivery (n=5) at term. Values are the



















Plate 7.1. Modulation of CRH immunostaining of first trimester
placenta
7.1.A. Placental villi obtained after suction termination of
pregnancy at 8 weeks gestation without pretreatment with
prostaglandins. CRH immunostaining is seen in the
syncytiotrophoblast.
7.I.B. Placental villi obtained after suction termination of
pregnancy at 8 weeks gestation pretreated with
prostaglandins. CRH immunostaining is seen in the
syncytiotrophoblast.
7.1.C. Placental villi obtained after termination of pregnancy at 8
weeks gestation with mifepristone and prostaglandins. CRH
immunostaining is seen in the syncytiotrophoblast. Note
there is no difference in the distribution or intensity of the
staining between the three modes of termination.




Plate 7.2. Modulation of CRH immunostaining of placenta and
fetal membranes at term (1)
7.2.A. Placental villi demonstrating positive CRH immunostaining
in syncytiotrophoblast from a normal vaginal delivery at
term.
7.2.B. Placental villi demonstrating positive CRH immunostaining
in syncytiotrophoblast from a caesarean section at term.
7.2.C. Placental villi demonstrating positive CRH immunostaining
in syncytiotrophoblast from a delivery induced with
prostaglandins at term. Note there is no difference in the
distribution or intensity of the 'Staining between the three
modes of delivery
7.2.D. Amnion demonstrating posMv-e CRH immunostaining
from a normal vaginal deliver}' at term.
7.2.E. Amnion demonstrating positive CRH immunostaining from
a caesarean section at term.
7.2.F. Amnion demonstrating positive CRH immunostaining from
a delivery induced with prostaglandins at term. Note there
is no difference in the distribution or intensity of the
staining between the three modes of delivery
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Plate 7.3. Modulation of CRH immunostaining of placenta and
fetal membranes at term (2)
7.3.A. Chorion demonstrating positive CRH immunostaining from
a normal vaginal delivery at term.
7.3.B. Chorion demonstrating positive CRH immunostaining from
a caesarean section at term.
7.3.C. Chorion demonstrating positive CRH immunostaining from
a delivery induced with prostaglandins at term. Note there
is no difference in the distribution or intensity of the
staining between the three modes of delivery
7.3.D. Decidua demonstrating positive CRH immunostaining from
a normal vaginal delivery at term.
7.3.E. Decidua demonstrating positive CRH immunostaining from
a caesarean section at term.
7.3.F. Decidua demonstrating positive CRH immunostaining from
a delivery induced with prostaglandins at term. Note there
is no difference in the distribution or intensity of the
staining between the three modes of delivery
The bar indicates 50|im
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CHAPTER 8
MODULATION OF PLACENTAL ACTH PRODUCTION
8.1 Introduction
As discussed in Chapter 6, ACTH is present in the placenta throughout
gestation. A role in influencing maternal and adrenal function during
pregnancy has been suggested (Jailer and Knowlton 1950; Silman and
Bergman 1953; Assali and Hammermetz 1954), potentially affecting the
HPA axis in the mother or the fetus by stimulating adrenal
steroidogenesis. This may be of particular significance in the fetus, since
the fetal adrenal cortex supplies the placenta with androgens for
oestrogen synthesis throughout pregnancy, and secretes Cortisol which is
essential for late fetal maturation. It has also been suggested that this
fetal maturation, and in particular maturation of the
hypothalamopitutaryadrenal axis, may be involved with the onset of
parturition.
In view of the potential role of ACTH in controlling the HPA axis
throughout pregnancy and its possible role in the onset of parturition,
this part of the study examined the localisation and content of IR-
ACTH in placenta and fetal membranes, and looked at the effects of
labour, exogenous prostaglandins and the administration of the
antiprogestin mifepristone on staining and peptide content. The POMC
gene expression in the same tissues was also investigated in terms of
localisation and quantification by in situ hybridisation.
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8.2. Materials and methods
8.2.1. Tissue collection
All gestations were calculated from the date of the last menstrual
period and were confirmed by ultrasound and/or clinical assessment.
Decidual and trophoblastic tissues were obtained from patients
undergoing therapeutic termination of pregnancy in the first trimester
by curettage with or without pretreatment with the synthetic
prostaglandin analogue gemeprost (16,16 dimethyl transA^
PGEimethylester) between 2 and 4 hours prior to the procedure and also
from patients undergoing therapeutic termination in the first and
second trimester using mifepristone 600mg orally 48 hours prior to
receiving a lmg gemeprost vaginal pessary. All patients aborted within
6 hours. Placenta and fetal membranes were also collected from
spontaneous vaginal deliveries at term (36-42 weeks gestation) by
elective casarean section (n=5), spontaneous vaginal delivery (n=7), and
by induction of labour using prostaglandin E2 (n=5) (all patients studied
received 2mg of PGE2 and all delivered within 24 hours). There was
no clinical evidence of infection in any patient, and there was no
histological evidence of inflammation in any of the tissues studied.
The materials and methods used were identical to those used in
chapter 6. Briefly, tissues were collected, fixed in 4% paraformaldehyde
and examined immunocytochemically and by in situ hybridisation
analysis. Peptide content in placental extracts was measured by
radioimmunoassay and sephadex chromatography was used to examine
the molecular size forms of placental ACTH.
8.3. Results
Positive immunostaining for ACTH was found in all placentas between
5 and 42 weeks gestation regardless of the method of termination of
pregnancy or delivery. In control slides, no positive ACTH
immunostaining was found where the primary antibody had been
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substituted by antibody dilution buffer, non-immunised rabbit serum or
CLIP antibody which had been preabsorbed with 5fiM human ACTH.
In the first trimester (from 5-12 weeks gestation) positive staining was
seen in the cytotrophoblast layer of cells, with none in the
syncytiotrophoblast. Positive staining was also seen in the cells of the
decidual stroma. The staining was faint when compared with tissue of
more advanced gestation. There was no difference in staining (see plate
8.1) or hybridisation signal (see plate 8.4), either in intensity or
localisation, between tissue obtained after suction curettage with or
without prostaglandin pretreatment compared with tissue obtained after
termination with mifepristone and prostaglandins.
From the second trimester onwards, positive ACTH immunostaining
was seen in the syncytiotrophoblast. The staining increased in intensity
withn advancing gestation. In the amnion the staining was particularly
pronounced in the epithelial layers with also some staining in the
subepithelial layer. In the chorion staining was seen mainly in the
reticular layer. Cells of the decidual stroma stained positively
throughout gestation.
There was no difference in staining (see plates 8.2. and 8.3.) or
hybridisation signal (see plate 8.5) in tissues obtained after elective
caesarean section (not in labour) at term compared with spontaneous
delivery at term. There was no difference in staining or signal intensity
in tissue obtained after labour induced with prostaglandins compared
with that from spontaneous delivery
Radioimmunoassay of the placental extracts revealed a significant
(p<0.01) increase in ACTH content in the third trimester. There was no
significant difference in placental ACTH content at term with different
modes of delivery (Fig 8.2), or in the first trimester after the
administration of prostaglandin E2 or the antiprogestin mifepristone (Fig
8.1). Mean value with standard errors are as follows; first trimester
termination using curettage with (6.91±1.54pg/mg protein) and without
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(7.1+0.97 pg/mg protein) pretreatment with prostaglandins, termination
using mifepristone and prostaglandins (8.03±1.92 pg/mg protein), (see
figure 8.1) Mean values of placental ACTH content for spontaneous
delivery were 32.11±5.78 pg/mg protein, for elective caesarean section
were 28.37±6.02 pg/mg protein and for induced labour were 26.6±13.26
pg/mg protein. Mode of delivery also had no effect on the ACTH
content of fetal membranes (see fig 8.3).
Sephadex G50 chromatography revealed that ACTH from placental
extracts and human ACTH (1-39) standard eluted with an identical
retention time indicating that both had an identical molecular weight
(see fig 6.4).
Image analysis of the in situ hybridisation studies showed that there
was no significant difference in grain density, and therefore POMC gene
expression, between first trimester placentas collected after termination
with curettage with(0.8±0.085grains/cm2xl 05) and without
(0.83±0.18grains/cm2xl05) prostaglandins and with mifepristone and
prostaglandins (0.65±0.06 grains/cm2xl05) (see fig 8.4). At term there was
no difference in placentas collected after spontaneous
(3.08±0.18grains/cm2xl05), induced (2.81±0.075grains/cm2xl05) and
caesarean delivery (2.52±0.45grains/cm2xl05) (see fig 8.5).
8.4. Discussion
As discussed in chapter 6 positive ACTH immunostaining in the
placenta throughout pregnancy. ACTH immunostaining is seen in the
cytotrophoblasts and decidual stroma as early as five weeks gestation
and in the fetal membranes from the second trimester onwards (the
earliest time these tissues could be collected). Extraction of peptide from
the placenta and radioimmunassay for ACTH revealed detectable levels
at al stages of pregnancy investigated. The intensity of this staining and
POMC mRNA levels were unaffected by method of termination of
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pregnancy consistent with the finding that there was no significant
difference in peptide content between the different groups of placenta.
The concentrations of ACTH were similar to those reported previously
by Liotta et al (1977), Rees et al (1975) and Odagiri et al (1989).
The intensity of the immunostaining increased throughout gestation but
the localisation changed from the cytotrophoblast in the first trimester
to the syncytiotrophoblast thereafter. The placental ACTH content and
POMC gene expression were also significantly greater at term than in
the first trimester, but, like staining intensity, they were unaffected by
labour or the administration of exogenous prostaglandins. Previous
studies of placental ACTH immunostaining (Al-Timini and Fox 1986)
localised ACTH to the syncytiotrophoblast and found no change in the
intensity or localisation of the immunostaining throughout gestation.
These studies did not investigate the effect of labour, prostaglandins or
mifepristone on ACTH immunostaining. Furthermore, some studies of
placental ACTH content have not shown any variation in placental
ACTH content throughout pregnancy (Liotta et al 1977; Rees et al 1975;
Odagiri et al 1979 ) (as discussed in chapter 6) but again did not
consider the effects of mode of delivery on placental ACTH content.
The finding of increased POMC gene expression strongly supports the
placental ACTH content results which were in conflict with these
previous studies.
This is the first study to localise and quantify POMC gene expression in
the placenta throughout gestation using in situ hybridisation. Previous
studies using northern analysis (Cheng et al 1986) has identified POMC
mRNA in human placenta but only at term. In rat placenta, the
expression of POMC gene appears to be constitutive as the concentration
of POMC mRNA does not change during pregnancy (Cheng et al 1986).
This study clearly showed that the POMC gene is expressed in the first
trimester and that this expression increases in the final trimester prior
to labour. Labour itself did not appear to affect POMC gene expression,
as there was no significant difference between hybridisation signal in
placentas collected after labour and those collected at elective caesarean
section. The POMC gene is also expressed in the fetal membranes,
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consistent with the finding of positive immunostaining and the
extraction of ACTH from these tissues. In the first trimester there was
no difference in POMC gene expression with method of termination,
suggesting that, at least in the short term, prostaglandins and
mifepristone have no effect on placental ACTH output.
The increase in peptide content, increase in intensity of
immunostaining and increase in POMC gene expression as seen with
in situ hybridisation support the hypothesis that placental ACTH rises
prior to labour. The biological significance of this is uncertain. The
demomstration of ACTH immunoreactivity from early to late gestation
suggests that the placenta may exert an effect on the maternal and/or
fetal adrenal throughout the whole of pregnancy. In addition placental
ACTH may be involved with placental CRH in the control of the
onset of parturition. It has been suggested that activation of the fetal
hypothalamo-pituitary-adrenal axis is linked to the onset of parturition.
Placentally produced peptides may have a key role in this. Placental
CRH could pass to the fetal circulation, stimulating the release of
ACTH from the fetal pituitary. This in turn would cause the release of
Cortisol from the adrenal. This Cortisol may both increase DHEAS
resulting in increased output by the placenta, and also stimulate
placental CRH production in a positive feedback loop. The effects of
placental CRH to increase prostaglandin production (see chapter 1) could
lead to ripening of the cervix and myometrial contractility (Challis and
Hooper 1989) And ultimately birth. Placental ACTH also passes into the
fetal circulation, and may affect fetal Cortisol. The finding of a rise in
placental ACTH in the third trimester supports the hypothesis that it
may be involved in this process. However the finding that its
production is unaffected by labour suggests that it may be involved in
the maturation of the fetal HPA axis through pregnancy rather than
being a trigger for birth.
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Figure 8.1.
Immunoreactive ACTH concentrations measured by radioimmunoassay
in first trimester placental extracts collected after termination of
pregnancy induced by mifepristone (RU486) (n=5), curettage with
prostaglandin (STOP+C) (n=5), or curettage without prostaglandin (STOP-
C) ( n=5). Values are the mean ± SEM. There was no significant











Immunoreactive ACTH concentration measured by radioimmunoassay in
extracts of placenta collected after spontaneous (n=7), induced (n=5) or
caesarean delivery (n=5) at term. Values are the mean ± SEM. There































Immunoreactive ACTH concentration measured by radioimmunoassay in
extracts of amnion, chorion and decidua collected after spontaneous
(n=7), induced (n=5) or caesarean delivery (n=5) at term. Values are the























POMC gene expression measured by quantification of in situ
hybridisation performed on sections of placentas collected after
termination of pregnancy in the first trimester induced by mifepristone
(RU486) (n=3), curettage with prostaglandin (STOP+C) (n=3), or curettage
without prostaglandin (STOP-C) (n=3). Each histogram represents the
means of six random counts of the tissue grain density (background
non-specific counts have been subtracted) of each of three groups of









POMC gene expression measured by quantification of in situ
hybridisation performed on sections of placentas collected after
spontaneous (n=3), induced (n=3) or caesarean (n=3) delivery at term.
Each histogram represents the means of six random counts of the tissue
grain density (background non-specific counts have been subtracted) of
each of three groups of tissues. Values are the mean ± SEM. There was










Plate 8.1. Modulation of ACTH immunostaining of first trimester
placenta
8.1.A. Placental villi obtained after suction termination of
pregnancy at 8 weeks gestation without pretreatment with
prostaglandins. ACTH immunostaining is seen in the
cytotrophoblast.
8.I.B. Placental villi obtained after suction termination of
pregnancy at 8 weeks gestation pretreated with
prostaglandins. ACTH immunostaining is seen in the
cytotrophoblast.
8.l.C. Placental villi obtained after termination of pregnancy at 8
weeks gestation with mifepristone and prostaglandins.
ACTH immunostaining is seen in the cytotrophoblast. Note
there is no difference in the distribution or intensity of the
staining between the three modes of termination.
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Plate 8.2. Modulation of ACTH immunostaining of placenta and
fetal membranes at term (1)
8.2.A. Placental villi demonstrating positive ACTH
immunostaining in syncytiotrophoblast from a normal
vaginal delivery at term.
8.2.B. Placental villi demonstrating positive ACTH immunostaining
in syncytiotrophoblast from a caesarean section at term.
8.2.C. Placental villi demonstrating positive ACTH
immunostaining in syncytiotrophoblast from a delivery
induced with prostaglandins at term. Note there is no
difference in the distribution or intensity of the staining
between the three modes of delivery
8.2.D. Amnion demonstrating positive ACTH immunostaining
from a normal vaginal delivery at term.
8.2.E. Amnion demonstrating positive ACTH immunostaining
from a caesarean section at term.
8.2.F. Amnion demonstrating positive ACTH immunostaining
from a delivery induced with prostaglandins at term. Note
there is no difference in the distribution or intensity of the
staining between the three modes of delivery




Plate 8.3. Modulation of ACTH immunostaining of placenta and
fetal membranes at term (2)
8.3.A. Chorion demonstrating positive ACTH immunostaining
from a normal vaginal delivery at term.
8.3.B. Chorion demonstrating positive ACTH immunostaining from
a caesarean section at term.
8.3.C. Chorion demonstrating positive ACTH immunostaining
from a delivery induced with prostaglandins at term. Note
there is no difference in the distribution or intensity of the
staining between the three modes of delivery
8.3.D. Decidua demonstrating positive ACTH immunostaining
from a normal vaginal delivery at term.
8.3.E. Decidua demonstrating positive ACTH immunostaining from
a caesarean section at term.
8.3.F. Decidua demonstrating positive ACTH immunostaining
from a delivery induced with prostaglandins at term. Note
there is no difference in the distribution or intensity of the
staining between the three modes of delivery
The bar indicates 50(im
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Plate 8.4. Modulation of POMC gene expression in first trimester
placenta
8.4.A &B Dark (A) and light (B) field micrographs of in situ
hybridisation of POMC mRNA in first trimester
placenta collected after termination of pregnancy with
mifepristone and prostaglandins.
8.4.C Negative control. Tissue shown in 8.4.A but using
sense probe. Note low level of non specific
hybridisation.
8.4.D&E. Dark (D) and light (E) field micrographs of in situ
hybridisation of POMC mRNA in first trimester
placenta collected after termination of pregnancy by
suction curettage without prostaglandins.
8.4.F Negative control. Tissue shown in 8.4.D but using
sense probe. Note low level of non specific
hybridisation.
8.4.G&H. Dark (G) and light (H) field micrographs of in situ
hybridisation of POMC mRNA in first trimester
placenta collected after termination of pregnancy by
suction curettage pretreated with prostaglandins. Note
there is no difference in grain density between the
three groups.
8.4.1 Negative control. Tissue shown in 8.4.G but using
sense probe. Note low level of non specific
hybridisation.
The bar indicates 50pm
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Plate 8.5. Modulation of POMC gene expression in term placenta
8.5.A & B Dark (A) and light (B) field micrographs of in situ
hybridisation of POMC mRNA in term placenta
collected after spontaneous delivery.
8.5.C Negative control. Tissue shown in 8.5.A but using
sense probe. Note low level of non specific
hybridisation.
8.5.D & E Dark (D) and light (E) field micrographs of in situ
hybridisation of POMC mRNA in term placenta
collected after delivery induced with prostaglandins.
8.5.F Negative control. Tissue shown in 8.5.D but using
sense probe. Note low level of non specific
hybridisation.
8.5.G & H Dark (G) and light (H) field micrographs of in situ
hybridisation of POMC mRNA in term placenta
collected after elective caesarean section at term.
8.5.1 Negative control. Tissue shown in 8.5.G but using
sense probe. Note low level of non specific
hybridisation.




9.1. Localisation of CRH within the Placenta and Fetal Membranes.
It was already well known that both CRH, and CRH mRNA are
detectable in placental extracts, in increasing quantities from the first
trimester onwards (Shibasaki et al 1982; Sasaki et al 1987 Frim et al
1988; Okamoto et al 1989). Correspondingly there is a rise in maternal
plasma CRH concentration during this time and a rapid fall is seen
within hours of delivery (Sasaki et al 1984; Goland et al 1986; Campbell
et al 1987; Laatikainen et al 1987b; Okamoto et al 1989). All these
observations suggested that the placenta both synthesises and releases
increasing amounts of CRH throughout pregnancy. CRH localisation has
also been described by three groups, but there is some discrepancy
between them. These studies set out to provide further evidence of the
exact cellular localisation of placental CRH by immunocytochemistry,
and to attempt to quantify its production throughout pregnancy by
peptide extraction. The role of CRH in the placental-fetal unit is
unclear, and it was hoped that information about the precise
localisation CRH within particular cell types may provide evidence for
the site of action of CRH. In addition, an investigation into the
production of CRH with different modes of delivery may provide
insight into its potential role in parturition.
Early studies of the localisation of CRH within the placenta suggested
that CRH immunoreactivity was located in the cytotrophoblasts
(Petraglia et al 1987; Saijonmaa et al 1988). However, as discussed in
Chapter 1, this cell type decreases in number during pregnancy reaching
relatively small numbers by term (Gosseye and Fox 1984). As mentioned
above, it is at this time that the CRH content of the placenta,
maternal plasma and amniotic fluid is at its highest (Laatikainen et al
1988; Maser-Gluth et al 1987). More recently CRH has been localised to
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the syncytiotrophoblasts as well as the amnion, chorion and decidua
(Riley et al 1991). These results are consistent with the observation that
syncytiotrophoblasts are the most numerous cells at term. In addition,
CRH is released when cells from these tissues are cultured in vitro
(Jones et al 1989; Jones and Challis 1989; Jones and Challis 1990a).
The finding of CRH immunostaining in the syncytiotrophoblasts as
early as five weeks gestation and in the amnion and chorion from 13
weeks was consistent with the detection of CRH by radioimmunoassay
in placental extracts in the first trimester. These results contradicted the
findings of Riley et al who could not detect CRH in placenta before the
second trimester. However, CRH is detectable in maternal plasma
during the first trimester, albeit at low levels, and CRHmRNA has been
demonstrated in the placenta by Northern analysis as early as seven
weeks gestation (Frim et al 1988). In addition, in vitro studies of
cultured placental and amnion cells at 12 weeks gestation have shown
a significant output of CRH, data which supports the finding of positive
immunostaining in the first trimester (Jones and Challis 1990a). In
previous studies positive immunostaining has been reported in
cytotrophoblasts (Petraglia et al 1987a; Saijonmaa et al 1988). Saijonmaa
et al (1988) used a high concentration of antibody with no preabsorbed
control and found immunostaining in the first trimester but not at
term. These workers attributed this to the relatively small numbers of
cytotrophoblast cells at term but this does not account for the very high
levels of CRH found in the placenta at this time. Petraglia et al (1987a)
found CRH immunopositive staining in the cytotrophoblasts at term
but again this does not account for the high levels of circulating CRH.
The findings of the study described in Chapter 5 demonstrating CRH
immunostaining in the large numbers of syncytiotrophoblasts at term
are consistent with the high maternal plasma and amniotic fluid levels
and agrees with the immunohistochemical findings of Riley et al
(1991). Furthermore, in vitro studies of cultured placental, amnion,
chorion and decidual cells at term have demonstrated significant CRH
output at this time. The difference between these studies are difficult to
explain but may relate to different methods of tissue fixation and
collection, or to the antibodies used.
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The finding of CRH immunostaining in the amnion, chorion and
decidua is consistent with the results of primary cultures of these
tissues (Jones, Brooks and Challis 1989) at term (Jones and Challis 1989)
and in the first trimester (Jones and Challis 1990). These studies
concluded that the fetal membranes produce CRH both in early and late
gestation. In addition, CRHmRNA has been demonstrated in the
amnion (Okamoto et al 1990) and decidua (Petraglia et al 1992). The
results of the study described in chapter 5 also agree with the findings
of Riley et al (1991) who also found positive immunostaining in the
epithelium and subepithelial cells of the amnion, in the trophoblast
layer, in some cells of the reticular and cellular layers of the chorion
and in the stromal cells of the decidua.
9.2. Localisation of ACTH within the Placenta and Fetal Membranes.
In situ hybridisation enables the precise localisation and identification of
individual cells which contain a specific nucleic acid sequence. When
used with immunocytochemistry, both the mRNA transcribed from the
gene itself, and the gene product translated from mRNA can be
localised to a particular cell type giving very strong evidence for the
site of synthesis. This is the first study to identify POMC gene
expression within the placenta by in situ hybridisation. Both the
localisation of peptide and its quantification are supported by the
localisation and level of expression of POMCmRNA.
Previous studies have found maternal plasma ACTH concentration to
rise during pregnancy (Rees et al 1975; Carr et al 1981) and synthesis in
vitro of both bioactive and immunoreactive ACTH by human placenta
at term and in the first trimester has been reported. In contrast to
rising levels of plasma ACTH recorded by some groups, it has also been
suggested that placental ACTH levels stay constant during pregnancy
(Liotta et al 1977, Rees et al 1975, Odagiri et al 1979), although there is
disagreement over the actual levels of peptide present (Genazzini et al
1975). In addition, perifusion of placental fragments produced a release
of bioactive ACTH of similar concentration at both early and late
gestation. Immunoreactive POMC- derived peptides have been detected
149
in the human placenta and de novo synthesis of POMC and its
derived peptides has been demonstated in cultures of human
trophoblasts (Liotta et al 1977, Mulder et al 1986, Waddell et al 1992)
Furthermore, POMC mRNA has been detected in human placenta at
term (Cheng et al 1986) but levels in the rat were shown to be constant
throughout pregnancy. Immunoreactive ACTH has been localised
immunocytochemically to the syncytiotrophoblast (Al-Timini & Fox
1986) and showed a similar intensity of staining in first and third
trimester placentae, agreeing with those studies that indicated little or
no variation in the levels of placental ACTH secretion throughout
pregnancy (Liotta et al, 1977, Odagiri et al 1979, Demura et al, 1982) In
view of the potential role of ACTH in controlling the HPA axis
throughout pregnancy and its possible role in the onset of parturition,
this part of the study examined the localisation and content of IR-
ACTH in placenta and fetal membranes throughout gestation and the
expression of the POMC gene in the same tissues. The results detailed
in chapter 6 provide strong evidence for both the site of synthesis
and expression of placental POMC peptides. The finding of an
increase in the intensity of ACTH immunostaining in cytotrophoblasts
seen with gestation is supported strongly by the rise in placental
ACTH content and increased POMC gene expression over the same
time.
9.3. The modulation of placental CRH.
Both the intensity of CRH immunostaining and placental CRH content
increases with increasing gestation. Neither the intensity of the staining
nor peptide content changed with spontaneous compared with caesarean
delivery suggesting that labour may have no effect on placental CRH
production. In vitro studies (Jones et al 1989) of primary cultures of
placental and fetal membrane cells showed increased ability to produce
CRH in cells obtained after spontaneous delivery on day 2 of culture
when compared to tissue from elective caesarean section. This increase,
however, was not seen on subsequent days of culture. It was suggested
that this represented release of preformed CRH on day 2 whereas later
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release was due to both synthesis and secretion. Maternal plasma CRH
concentrations have been shown to remain at constant levels during the
first, second and third stages of labour (Laatikainen et al 1987b).
The hypothesis that progesterone may have a regulatory effect on
placental CRH production was tested using the antiprogestogen,
mifepristone. There was no difference in intensity of staining in
placentas from patients pretreated with mifepristone compared to those
who were not, and in addition to this, there was no significant
difference in the CRH content of these placentas compared with those
obtained after suction termination. Forty-eight hours of exposure to
mifepristone is likely to be a sufficient duration to produce an increase
in peptide synthesis, however the anti-glucocorticoid side effects of
mifepristone may counteract its anti-progestogenic effects since
glucocorticoids have been shown to stimulate CRH release by the
placenta and fetal membranes in vitro (Jones et al., 1989; Jones & Challis,
1990a). Another explanation for the lack of effect of mifepristone on
CRH concentration may relate to the early stage of gestation when these
studies were conducted. In vitro studies have demonstrated that
progesterone inhibits CRH release by the placenta at term (Jones et al.,
1989) but has no effect in early pregnancy (Jones & Challis, 1990a). It may
be that mifepristone given later in pregnancy would affect output of
CRH whereas in the first trimester it does not. Nonetheless, treatment
with mifepristone results in a clinical effect producing abortion. It
would appear from the data that this effect of mifepristone is not
mediated via the induction of CRH synthesis as CRH appeared to be
constitutively present in all tissues studied.
9.4 The modulation of placental ACTH.
It is known that the placenta is not merely a storage site for POMC-
derived peptides but can actively synthesise them (Liotta and Krieger
1980). There is disagreement over the levels of placental ACTH during
pregnancy. Some studies of placental ACTH content have not shown
any variation in placental ACTH content throughout pregnancy (Liotta
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et al 1977; Rees et al 1975; Odagiri et al 1979 ) There is also
disagreement as to whether ACTH plasma concentrations change with
pregnancy (Liotta et al 1977; Rees et al 1975; Genazzani et al 1975) One
study showed constant plasma levels during pregnancy with a rise
after labour (Laatikainen et al 1987). The study descibed in chapter 6
provided strong evidence of a rise in placental ACTH throughout
pregnancy. However ACTH content and POMC gene expression were
not affected by labour or the administration of prostaglandins or
mifepristone in the first trimester. Previous studies of placental ACTH
immunostaining (Al-Timini and Fox 1986) localised ACTH to the
syncytiotrophoblast but found no change in the intensity or localisation
of the immunostaining throughout gestation. Immunostaining is not a
reliable method for the quantification of peptide content and these
studies were not supported by separate measurements of ACTH content.
The effects of labour, prostaglandins or mifepristone on ACTH
immunostaining have also never previously been investigated.
This is the first study to localise and quantify POMC gene expression in
the placenta throughout gestation using in situ hybridisation. Previous
studies using northern analysis (Cheng et al 1986) have identified
POMC mRNA in human placenta but only at term. In rat placenta, the
expression of POMC gene appears to be constitutive as the concentration
of POMC mRNA does not change during pregnancy (Cheng et al 1986).
This study clearly showed that the POMC gene is expressed in the first
trimester and that this expression increases in the final trimester prior
to labour. Labour itself did not appear to affect POMC gene expression,
as there was no significant difference between hybridisation signal in
placentas collected after labour and those collected at elective caesarean
section. The POMC gene is also expressed in the fetal membranes,
consistent with the finding of positive immunostaining and the
extraction of ACTH from these tissues. In the first trimester there was
no difference in POMC gene expression with method of termination,
suggesting that, at least in the short term, prostaglandins and
mifepristone have no effect on placental ACTH output.
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9.5. ACTH and CRH and parturition
As described in chapter 1, it has been hypothesised that activation of
the hypothalamopituitary axis plays a central role in the onset of
parturition. This conclusion has been drawn largely from what is
known about parturition in sheep. Although there are major
differences, human and ovine parturition also share some common
mechanisms. In the sheep, activation of the HPA axis controls the
onset of parturition. Over the last few weeks of gestation, the fetal
hypothalamus releases CRH stimulating the production of ACTH by the
pituitary (Brooks and Challis 1988). The resulting increased Cortisol
production by the fetal adrenal increases the activity of placental 17-
hydroxylase which is required to convert progesterone to oestrogen
(Flint et al 1975). The relative increase in oestrogen (a myometrial
stimulant) compared to progesterone (a myometrial relaxant) results in
myometrial excitability, prostaglandin production and uterine sensitivity
to oxytocin. As discussed in chapter 1, prostaglandins appear to
constitute the final common pathway in women as well as sheep. The
main difference between the species is that human placenta lacks 17-
hydroxylase and therefore cannot convert progesterone to oestrogen.
Indeed, there is no change in the levels of these steroids at the time
of labour (Liggins 1983). Although there is little evidence to suggest that
the fetal HPA axis influences placental steroids in the human as it does
in the sheep, it has been suggested that activation of the axis is
involved in the onset of human labour. The object of these studies was
to support or refute this claim. The evidence supporting activation of
the HPA axis in the initiation of human labour was based on the
finding that maternal plasma CRH rose exponentially in the third
trimester, peaking at delivery and high levels are found in the
umbilical cord plasma and amniotic fluid at term (Goland et al 1988;
Sasaki et al 1987: Campbell et al 1987). As discussed earlier this CRH is
placentally derived and the study described in chapter 5 showed a
gestationally related increase in placental CRH content which supports
these findings. In addition, this study located the CRH within the
syncytiotrophoblast, a cell type which is found in large numbers at
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term, consistent with the increased peptide content found at this time.
Plasma ACTH has been reported to rise in the third trimester (Rees et
al 1975; Genazzani et al 1975; Carr et al 1981; Okamoto et al 1989; Smith
et al 1990), although there is disagreement as to whether placental
ACTH content changes with gestation. Concentrations reported by Liotta
et al (1977), Rees et al (1975) and Odagiri et al (1979) are essentially
similar. Significantly lower levels were reported by Genazzani et al
(1975), but there was lack of parallelism in the immunoassay of
placental extract with standard ACTH. The findings of the study
described in chapter 6 were of an increase in placental ACTH content
in parallel with increased POMC gene expression, highly supportive of
the hypothesis that placental ACTH increases with gestation. In vitro
studies have also suggested that placental CRH may directly stimulate
placental ACTH production (Petraglia et al 1987b) consistent with the
findings of these studies of a rise in both these peptides.
In vitro studies using monolayer cultures of placenta and fetal
membranes have shown increasing output of CRH after spontaneous
labour than after elective caesarean section (not in labour) (Jones et al
1989). However, the results of the study described in chapter 7 do not
agree with this finding, as there was no significant difference in
placental CRH content, between these two groups. In addition, similar in
vitro work has shown CRH output by cultured placenta is inhibited by
progesterone. Again, it might be expected that placental tissue collected
after termination of pregnancy with the antiprogestin mifepristone
would show an increase in CRH content, but there was no significant
difference between tissues collected by simple curettage and those
collected after the administration of mifepristone and prostaglandins.
In vitro cell culture studies have also demonstrated interactions
between the activation of the hypothalamo-pituitary-adrenal axis and
the control of prostaglandin production. ACTH output is stimulated by
the addition of PGE2 and PGF2a and this effect is blocked by CRH
antagonists, indicating that CRH is an intermediary in this process
(Petraglia et al 1987b). In addition CRH is able to stimulate PGE2 and
PGF2a production from cultured human placenta and fetal membranes
154
thus forming a positive feedback loop between prostaglandins, CRH
and ACTH. However placental and fetal membrane contents of both
CRH and ACTH were not affected by the administation of
prostaglandins for the induction of labour at term, nor were placental
contents of these peptides affected by the administration of
prostaglandins for termination of pregnancy in the first and second
trimesters. Consistent with these findings, there was no increase in
levels of POMCmRNA in the same tissues, indicating that there was
no increase in gene expression.
The results of these studies support previous findings of an increase in
placental CRH with advancing gestation and provide conclusive
evidence of a rise in not only ACTH content, but POMC gene
expression with advancing gestation. This study is the first to localise
POMC gene expression in the placenta by in situ hybridisation.
Although the results of the studies investigating the modulation of
CRH and ACTH secretion by labour or the administration of
prostaglandins do not directly support the hypothesis that activation of
the hypothalamo-piuitary-adrenal axis is implicated in the onset of
human labour, it appears that these hormones are present constitutively
in placenta and fetal membranes. This does not preclude more subtle
changes in the synthesis or export of these peptides which may be
important in the physiological or pharmacological control of uterine
contractility. The constitutive presence of ACTH and CRH suggests that
they may have a role in the general endocrine milieu of the placenta
rather than being simply related to parturition. In addition, it is known
that both these peptides enter the fetal circulation and may affect the
fetal hypothalamo-pituitary-adrenal axis. In the fetal sheep, activation of
the hypothalamo-pituitary-adrenal axis with resultant Cortisol
production is linked to organ maturation by enhancing enzyme
activities (Liggins 1983) and a similar mechanism may exist in humans.
Indeed, high levels of CRH have been associated with lung maturation
in vivo in humans (Laatikainen et al 1988) and in the developing
mouse lung (Keegan et al 1994). This effect may be to facilitate fetal
lung maturation by glucocorticoids, either by the stimulation of ACTH
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from the pituitary or via a paracrine loop involving ACTH synthesis in
the lung itself (Texier et al 1991)
It has been known for a long time that the human placenta secretes
large quantities of specific proteins, peptide hormones and steroids,
many of which have an unknown function in both maternal and fetal
circulations. This has led to suggestions that these hormones are merely
waste products of a poorly understood phenomenon (Gordon and Chard
1979). This would seem to be an enormous waste of both energy and
amino acids and instead it has been hypothesised that they are present
to provide the trophoblast with information about the maternal
environment, enabling it to function as a coherent unit (Chard 1993).
This may partly account for the presence of ACTH and CRH in the
placenta and would not rule out any potential effect on the fetus and a
possible role in the onset of parturition.
Conclusions: Placental CRH is located within the syncytiotrophoblasts
of the human placenta and within the fetal membranes and decidua. Its
concentration rises with advancing gestation and is unaffected by labour,
the administration of exogenous prostaglandins or mifepristone. ACTH
is located within the cytotrophoblasts in early pregnancy and the
syncytiotrophoblasts after the end of the first trimester. Placental content
increases with advancing gestation in parallel with POMC gene
expression, and these are unaffected by labour, or by exogenous
prostaglandins and mifepristone. Thus both CRH and ACTH appear to
be constitutively present in the human placenta throughout pregnancy.
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Appendix 1. Preparation of TESPA (3, aminopropyltriethoxysilane)
coated slides.
Washed slides were cleaned and coated by the following procedures:
1. Baked at 250°C for 6 hours.
2. Immersed in a 2% solution of TESPA in acetone for 30 seconds.
3. Allowed to air dry and then reimmersed in 2% TESPA for 30
seconds.
4. Immersed in acetone for a further 30 seconds.
5. Washed in Still-plus distilled water for 30 seconds.
6. Allowed to air dry.
7. The slides were stored at room temperature.
(Gloves were worn to avoid contamination with RNAse.
Appendix 2. In situ hybridization solution.
A. Solutions.
1. Phosphate buffered saline (PBS), pH 7.2(100 mM),




Made up to 1 litre with Still-plus water.
2. 4% Paraformaldehyde.
4g of paraformaldehyde was dissolved in 100ml of lOmM PBS by
heating to 60°C, with stirring.The solution was allowed to cool
and the pH adjusted to 7.4 with concentrated NaOH. The
solution was made fresh every 36 hours.
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3. 20X Standard Saline Citrate (20XSSC)
175.3g of NaCl and 88.2g of sodium citrate were dissolved in
800mls of Still-plus water, adjusted to pH 7.0 with IN HC1, and
made up to 1L and then autoclaved.
4. 0.2% Glycine.
70mg of glycine were dissolved in 350mls of Still-plus water.
This solution was made up fresh every day.
5. Proteinase K
The proteinase K was dissolved in Still-plus water at a stock
concentration of lOmg/ml and stored at -20°C.
6. IN HC1: made up with Still-plus water and autoclaved.
7. 0.1M Tris/HCl
12.lg of Tris base was dissolved in 800mls of Still-plus water and
the pH was adjusted to 7.5 with concentrated HC1. The volume
of the solution was made up to 1L with Still-plus water.
8. RNAse buffer: 20mM Tris?HCl pH 7.6 containing ImM EDTA.
B. Hybridization buffer.
1. Deionized Formamide.
50 ml of formamide were mixed with 5g of mixed-bed ion
exchange resin (Bio-Rad AG 501-x8, 20-50 mesh). The solution
was stirred overnight at 4°C, filtered twice with whatman No.l
filter paper and stored at 20°C.
2. Denhardt's solution (50x).
5mls of Still-plus water were added to each vial of Denhart's
(50mg each of BSA, Ficoll and PVP). The solution was aliquoted
and stored at -20°C.
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3. Salmon testis denatured DNA (lOmg/ml)
4. Yeast transfer RNA (lOmg/ml)
20mg of yeast transfer RNA was dissolved in 2ml of DEPC
treated water and placed on ice for 30 mins, aliquoted and stored
at -20°C.
5. 50% (w/v) dextran sulphate.
lg of dextran sulphate was dissolved in 2ml of Still-plus water
and stored at 4°C.
6. 1M DTT
5g of DTT was added to 32.4 ml Still-plus water.
C. Hybridization buffer formulae
1. Digoxigenin-labelled Oligonucleotide Hybridisation buffer.
Stock concentration Final concentration
100% deionized formamide 43%/37%
20x SSC 3x
50x (l%w/v) denhardt's 0.1%
50%(w/v) dextran sulphate 4%
10mg/ml tRNA 200pg/ml
lOmg/ml salmon testis DNA 200jig/ml
1M DTT lOmM
2. 35s -labelled Oligonucleotide hybridisation buffer.
As above
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3. 35s-labelled Riboprobe hybridisation buffer.
Stock concentration Final concentration
100% deionised formamide 50%
25x SSPE 5x
50x (l%w/v) denhardt's 0.1%
lOmg/ml yeast tRNA 200pg/ml
lOmg/ml salmon testis DNA 200pg/ml
10% SDS 0.1%
1M DTT lOmM
Appendix 3. Probe labelling.
1. End-terminal oligonucleotide labelling with 35g
5x Tailing buffer lOpl
(500mM potassium cacodylate,pH 7.2,10mM CoCl2lmM DTT)
DNA (0.1 pM) 4pl
35s dATP (Amersham) (lpM) 4pl
Terminal Transferase (100 units) 5pl
Water 14pl
1. The reaction mixture was incubated for five minutes at 37°C in
order to add 10-15 bases.
2. 375pl TE (lOmM Tris-HCl, ImM EDTA ,pH 7.6), 25pl 4M NaCl
and 25pg/ml of yeast tRNA were added.
3. 450pl of phenol/chloroform/isoamyl alcohol were added (50:49:1)
4. The top (aqueous) phase was extracted with chloroform/ isoamyl
alcohol (49:1)
5. The top (aqueous ) phase was mixed with 1ml of ice-cold absolute
ethanol and precipitated at -20°C for 1 hour.
6. The sample was spun and the pellet washed twice with ethanol.
7. The pellet was dried in air and then reconstituted in 50pl TE and
lpl 5M DTT.
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8. lja.1 aliquots were added to 2mls of scintillation fluid and counted
in a beta counter.







lOjul5x Terminal transferase buffer
Terminal Transferase 25 units
The 50(il reaction mixture was mixed in a small eppendorf tube and
then incubated at 37°C for 2 hours. 2.5|il of 0.5M EDTA was added to
stop the reaction, the samples were run on a polyacrylamide gel to











The samples were run at 150V for 2 hours
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Polymerase (SP6 or T7)
1. The reaction mixture was incubated at 40°C for 1 hour, respiked
with a further 2gl SP6 and then incubated at 40°C for a further 1
hour
2. The DNA was precipitated with 1/10 volume of sodium acetate pH
6.0 and 2.5 volume of 95% ethanol.
3. The mixture was spun and the pellet washed with 100% and then
70% ethanol.
4. The pellet was dried in air and then resuspended in Stillplus
water.
5. l|il of the cDNA solution was counted in a beta counter.
Appendix 4. Autoradiography.
A. Photographic emulsion
1. 60mls of Kodak emulsion, stored at 4°C, was warmed at 45°C for
45 mins.
2. In the dark , the melted emulsion was carefully poured into a
dipping chamber and left for 10 mins for the bubbles to rise to the
surface.
3. Two clean, blank slides were dipped in to remove the bubbles.
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4. Each slide was dipped and slowly withdrawn from the emulsion.
The slides were left overnight standing vertically in a moist
chamber in the dark.
5. The slides were transfered into a light-tight box with a vial of silica
gel to absorb the mosture.
6. The slides were left at 4°C to expose for 2-6 weeks.
B. Developing the slides.
1. The following solutions were cooled on ice to reduce their
temperatures to 15°C.
1. 350mls of Kodak developer.
2. 400mls of distilled water.
3. 350mls Kodak fixer (lin9 dilution)
In the dark, the slides were taken through
2. distilled water for 30 seconds
3. fixer for 10 mins.
The slides were then washed in distilled water before counterstaining
with haematoxylin and then dehydrated in clean graded ethanols.
Appendix 5. Preparation of solutions for immunocytochemistry.
1. 0.5M TRIS buffer.
60.5g of Tris(hydroxymethlmethylamine) was dissolved in 800mls of






make up to 1L with distilled water.
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3. Methanol/Hydrogen Peroxide solution (3%)
Hydrogen Peroxide (30%) 30mls
Methanol 270mls
4. Tris/HCl buffer .(0.05M)
0.5M Tris (pH 7.6) lOmls
distilled water 19mls
5. Trypsin Digestion solution (0.1%)
Trypsin (type II) 300mg
CaCl2 (dihydrate) 300mg
Distilled water 300ml
The pH was adjusted to 7.4 with concentrated sodium hydroxide.
6. Normal Sheep serum/ 5% Bovine serum albumin.
Normal sheep serum lOmls
Bovine serum albumin 2.5g




8. Avidin-Biotin complex Peroxidase conjugated. (DAKOPATTS)
Avidin 1 drop
Biotinylated horseradish 1 drop
peroxidase
Tris/HCl 5mls


















Appendix 6. Deprotection of oligodeoxynucleotide probes.
The CRH oligonucleotides were synthesised on a 391 DNA Synthesizet
(Applied Biosystem, PCR-MATE). The next day, the columns containing
the synthesised oligonucleotides was removed and the oligonucleotides
deprotected as follows:
1. The two ends of the column was connected to two sterile 10ml
syringes, one of which contained 2mls of cold ammonia (stored at
2. Ammonia was pushed through the column several times and
then left in the column for 30 minutes before transfer to a 15ml
sterile tube .
3. The solution, capped and sealed with labfilm, was incubated at
55°C in a waterbath overnight to deprotect the oligo.
4. 1/10 volume of 3M sodium acetate, pH 7.0 and 2x volume of
100% ethanol were added to a 400jil aliquot of the deprotected
oligo. After precipitation at -70°C for 15 minutes, the oligo was
4°C).
165
pelleted by centrifugation at full speed for 10 minutes in a
microcentrifuge.
5. The pellet was washed once with 500pl of 70% ethanol and freeze
dried.
6. The pellet was then resuspended in 200{il sterile water. The
concentration of oligonucleotide was determined by measuring the
O.D.260 lfJ-1 of oligo solution in 1ml of distilled water.
Appendix 7.
Solutions for ACTH radioimmunoassay.
Assay buffer









250 Kallikrein Inhibitor Units /ml Aprotinin
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